"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03391791","Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors",,"Terminated","No Results Available","Solid and Hematological Malignancies","Genetic: Genetically engineered T Cell Receptors","Number of subjects with specific Long Term Follow-Up adverse events (AEs), including serious adverse events (SAEs) associated with administration of autologous T cell receptors that have been genetically modified by lentiviral vectors.|Measurement of Replication Competent Lentivirus (RCL) in genetically modified T cells|Persistence of genetically modified cells in the body|Assess the pattern of vector integration sites if at least 1% of cells in the surrogate sample are positive for vector sequences by PCR|Overall Survival (OS) post-infusion","Adaptimmune","All","18 Years and older   (Adult, Older Adult)",,"2","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ADP-0000-003","February 28, 2018","July 24, 2018","July 24, 2018","January 5, 2018",,"January 7, 2021","Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centr, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03391791"
2,"NCT04093622","Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy",,"Recruiting","No Results Available","Hematological Malignancy","Genetic: Genetically engineered NK cells","Overall Survival (OS) post-infusion|Incidence of LTFU adverse events (AEs), including serious adverse events (SAEs) associated with administration of Fate Therapeutics genetically modified NK cell product that have been genetically modified by lentiviral vectors.","Fate Therapeutics","All","18 Years and older   (Adult, Older Adult)",,"72","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FT-004","October 4, 2019","July 2036","July 2036","September 18, 2019",,"March 5, 2021","Mayo Clinic, Phoenix, Arizona, United States|UC San Diego, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04093622"
3,"NCT01735604","Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",,"Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Biological: anti-CD20-CAR vector-transduced autologous T cells|Other: genetically engineered lymphocyte therapy","Occurrence of study related adverse events|Anti-tumor responses to CART-20 cell infusions","Chinese PLA General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-001","January 2013","May 2017","October 2018","November 28, 2012",,"September 29, 2015","Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01735604"
4,"NCT01343043","A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma","NY-ESO-1","Completed","Has Results","Neoplasms","Drug: NY-ESO-1(c259)T Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Objective Response Rate (ORR)|Duration of Overall Response|Progression Free Survival|Best Overall Response|Overall Survival|Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)|Number of Participants With Worst Post-Baseline Grade Results for Hematology Parameters|Number of Participants With Worst Post-Baseline Grade Results for Clinical Chemistry Parameters|Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-infused (NY-ESO-1 Genetically Engineered T) Cell Antibody Result|Concentration of Cytokines in Cytokine Release Syndrome (CRS) by CRS Status: Cohort 1: High NY-ESO-1 Expression Treated With Regimen A|Concentration of Cytokines in CRS by CRS Status: Cohort 2: Low NY-ESO-1 Expression Treated With Regimen A|Concentration of Cytokines in CRS by CRS Status: Cohort 3: High NY-ESO-1 Expression Treated With Regimen B|Concentration of Cytokines in CRS by CRS Status: Cohort 4: High NY-ESO-1 Expression Treated With Regimen C|Time to Maximum Persistence of NY-ESO-1 Genetically Engineered T Cells","GlaxoSmithKline","All","4 Years and older   (Child, Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","208466|ADP 04511|2015-005594-21","September 27, 2012","June 18, 2019","June 18, 2019","April 27, 2011","July 9, 2020","June 30, 2021","GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01343043/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01343043/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01343043"
5,"NCT03697824","Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a",,"Withdrawn","No Results Available","Neoplasms","Drug: GSK3377794|Drug: Pembrolizumab|Drug: Fludarabine|Drug: Cyclophosphamide","Number of subjects with treatment limiting toxicities (TLT)|Number of subjects with AEs|Severity of AEs|Number of subjects with serious adverse events (SAEs)|Number of subjects with AE /SAEs leading to pembrolizumab administration delay, interruptions, and withdrawals|Number of subjects with abnormal hematology parameters|Number of subjects with abnormal clinical chemistry parameters|Number of subjects with abnormal urine parameters|Number of subjects with abnormal vital signs|Eastern Cooperative Oncology Group (ECOG) performance scores|Lansky performance scores|Number of subjects with abnormal electrocardiogram (ECG) parameters|Overall Response Rate|Progression free survival|Disease Control Rate|Duration of Response|Time to Response|Maximum transgene persistence (Cmax)|Time to Cmax (Tmax)|Area under the time curve from zero to time t (AUC[0-t])|Number of subjects with NY-ESO-1/LAGE-1a expression in tumor tissues","GlaxoSmithKline|Merck Sharp & Dohme Corp.","All","10 Years and older   (Child, Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","209147","February 25, 2019","July 18, 2022","July 18, 2022","October 5, 2018",,"October 29, 2019",,,"https://ClinicalTrials.gov/show/NCT03697824"
6,"NCT03185494","Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",,"Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Biological: anti-CD19/22-CAR vector-transduced T cells","Occurrence of study related adverse events|Anti-tumor responses to tanCART19/22 cell infusions","Chinese PLA General Hospital","All","5 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-022","August 1, 2017","August 1, 2019","August 1, 2020","June 14, 2017",,"April 17, 2019","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03185494"
7,"NCT03097770","Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",,"Completed","No Results Available","Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Biological: anti-CD19/20-CAR vector-transduced T cells","Occurrence of study related adverse events|Anti-tumor responses to tanCART19/20 cell infusions","Chinese PLA General Hospital","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-020","April 1, 2017","May 10, 2019","January 31, 2020","March 31, 2017",,"September 2, 2020","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03097770"
8,"NCT02580747","Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso",,"Unknown status","No Results Available","Malignant Mesothelioma|Pancreatic Cancer|Ovarian Tumor|Triple Negative Breast Cancer|Endometrial Cancer|Other Mesothelin Positive Tumors","Biological: anti-meso-CAR vector transduced T cells","Occurrence of Study related adverse events|Anti-tumor responses to CART-meso cell infusions","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s2015-080-06","October 2015","November 2017","November 2018","October 20, 2015",,"October 20, 2015","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02580747"
9,"NCT02541370","Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133",,"Completed","No Results Available","Liver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer|Acute Myeloid and Lymphoid Leukemias","Biological: anti-CD133-CAR vector-transduced T cells","Occurrence of study related adverse events|Anti-tumor responses to CART-133 cell infusions","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s2015-080-03","June 2015","June 2019","June 2019","September 4, 2015",,"December 17, 2019","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02541370"
10,"NCT01864889","Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19","CART19","Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Biological: anti-CD19-CAR vector-transduced T cells","Occurrence of study related adverse events|Anti-tumor responses to CART-19 cell infusions","Chinese PLA General Hospital","All","5 Years to 90 Years   (Child, Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-005","April 2013","April 2017","April 2017","May 30, 2013",,"January 28, 2016","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01864889"
11,"NCT01586403","Transfer of Genetically Engineered Lymphocytes in Melanoma Patients",,"Active, not recruiting","No Results Available","Melanoma","Biological: Dose 1|Biological: Dose 2|Biological: Dose 3|Biological: Dose 4","Find dose of autologous T cell receptor","Loyola University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","203732|R44CA126461|P01CA154778","July 2012","September 2028","September 2028","April 26, 2012",,"October 30, 2020","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01586403"
12,"NCT02062827","Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma","M032-HSV-1","Recruiting","No Results Available","Recurrent Glioblastoma Multiforme|Progressive Glioblastoma Multiforme|Anaplastic Astrocytoma or Gliosarcoma","Biological: M032 (NSC 733972)","Highest safe dose/MTD (maximum tolerated dose) or maximally planned dose if no dose-limiting toxicity observed|Time to progression assessment|The time of survival assessment|The time of biologic assessment","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UAB-1317","November 25, 2013","September 2022","September 2023","February 14, 2014",,"October 13, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02062827"
13,"NCT05101213","Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients",,"Not yet recruiting","No Results Available","Adenovirus Infection|BK Virus Infection|Cytomegaloviral Infection|Hematopoietic and Lymphoid Cell Neoplasm|JC Virus Infection|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed","Biological: Virus-specific Cytotoxic T-lymphocytes","Feasibility of administering genetically engineered glucocorticoid receptor knock out virus specific cytotoxic T-lymphocyte (CTL) lines, as indicated by Overall Survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0332|NCI-2021-09078","December 1, 2021","January 1, 2023","January 1, 2023","November 1, 2021",,"November 1, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05101213"
14,"NCT03412877","Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer",,"Suspended","No Results Available","Endocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancer|Neuroendocrine Tumors","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Biological: Individual Patient TCR-Transduced PBL|Drug: Pembrolizumab (KEYTRUDA )","Response rate|Safety and tolerance","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180049|18-C-0049","September 6, 2018","March 23, 2027","March 23, 2028","January 29, 2018",,"January 29, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03412877"
15,"NCT02414269","Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",,"Active, not recruiting","No Results Available","Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer","Genetic: iCasp9M28z T cell infusions|Drug: cyclophosphamide|Drug: pembrolizumab","Composite measure of severity and number of adverse events (AEs); changes in (clinical laboratory test findings (hematologic and chemistry); and physical examination. (Phase I)|clinical benefit rate (phase II)|Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP) (Phase I)","Memorial Sloan Kettering Cancer Center|Bellicum Pharmaceuticals|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","113","Other|Industry|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-007","May 2015","April 2023","April 2023","April 10, 2015",,"November 1, 2021","Memoral Sloan Kettering Basking Ridge (Consent and Follow-Up), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Consent and Follow-Up), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent and Follow-Up), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (Consent and Follow-Up), Commack, New York, United States|Memorial Sloan Kettering Westchester (Consent and Follow-Up), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (Consent and Follow-Up), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02414269"
16,"NCT03967223","Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","IGNYTE-ESO","Recruiting","No Results Available","Neoplasms","Drug: Letetresgene autoleucel (lete-cel, GSK3377794)|Drug: Fludarabine|Drug: Cyclophosphamide","Substudy 1: Overall response rate (ORR)|Substudy 2: Overall response rate (ORR) as assessed by central independent review|Substudy 1 and 2: Time to response|Substudy 1 and 2: Duration of response (DOR)|Substudy 1 and 2: Disease control rate (DCR)|Substudy 1 and 2: Progression free survival (PFS)|Substudy 1 and 2: Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity|Substudy 1 and 2: Number of participants with replication competent lentivirus (RCL)|Substudy 1 and 2: Number of participants with insertional oncogenesis (IO)|Substudy 2: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis parameters|Substudy 1 and 2: Maximum transgene expansion (Cmax) of letetresgene autoleucel|Substudy 1 and 2: Time to Cmax (Tmax) of letetresgene autoleucel|Substudy 1 and 2: Area under the concentration/persistence time curve from zero to time t (AUC[0-t]) of letetresgene autoleucel|Substudy 2: Overall response rate (ORR) as determined by the local investigators|Substudy 2: Overall Survival (OS)|Substudy 2: Number of participants with positive anti-drug antibodies (ADA) and titers of ADA against letetresgene autoleucel","GlaxoSmithKline","All","10 Years and older   (Child, Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","208467","December 31, 2019","November 30, 2022","July 31, 2026","May 30, 2019",,"November 17, 2021","GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Lyon cedex 08, France|GSK Investigational Site, Pessac cedex, France|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Rozzano (MI), Lombardia, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03967223"
17,"NCT04536922","Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab",,"Withdrawn","No Results Available","Metastatic HPV-16 Positive Squamous Cell Anal Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Drug: Pembrolizumab (KEYTRUDA(R))|Biological: Individual Patient TCR-Transduced PBL","Treatment","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","0","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10000163|000163-C","January 27, 2021","January 27, 2021","January 27, 2021","September 3, 2020",,"February 1, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04536922"
18,"NCT01349387","Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing","METFORGENE","Completed","No Results Available","Type 2 Diabetes","Drug: Metformin","Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR","Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010-A01389-30|2011-000128-13","May 2011","November 2011","January 2012","May 6, 2011",,"February 9, 2012","Centre Hospitalier Sud Francilien, Corbeil Essonnes, France",,"https://ClinicalTrials.gov/show/NCT01349387"
19,"NCT04135092","Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab",,"No longer available","No Results Available",,"Biological: Individual Patient TCR Transduced PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Drug: Pembrolizumab",,"National Institutes of Health Clinical Center (CC)",,"Child, Adult, Older Adult",,,"NIH","Expanded Access:Individual Patients",,"209950",,,,"October 22, 2019",,"September 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04135092"
20,"NCT02498912","Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors",,"Active, not recruiting","No Results Available","Solid Tumors","Procedure: Production of Genetically-modified T cells|Drug: Cyclophosphamide|Device: IP Catheter Insertion|Genetic: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Drug: Fludarabine","maximum tolerated dose (MTD)|evidence of anti-tumor activity","Memorial Sloan Kettering Cancer Center|Stanford University|Juno Therapeutics, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-014","August 2015","August 2022","August 2022","July 15, 2015",,"February 8, 2021","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02498912"
21,"NCT03240861","Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer","NYESO SCT","Recruiting","No Results Available","HLA-A*0201 Positive Cells Present|Locally Advanced Malignant Neoplasm|NY-ESO-1 Positive|Unresectable Malignant Neoplasm|Sarcoma","Other: 18F-FHBG|Biological: Aldesleukin|Drug: Busulfan|Biological: Cellular Therapy|Procedure: Computed Tomography|Biological: Filgrastim|Drug: Fludarabine|Procedure: Leukapheresis|Drug: Plerixafor|Procedure: Positron Emission Tomography","Incidence of dose limiting toxicity|Detection of replication competent retrovirus and replication competent lentivirus|Duration of overall complete response|Duration of overall response|Persistence of transduced T cells|Engraftment and persistence of transduced progeny T cells|Engraftment and persistence of transduced T cells and progeny T cells|Feasibility of generation NY-ESO-1 TCR transgenic T cells and NY-ESO-1 TCR/sr39TK transgenic stem cells that meet the lot release criteria|Immunological monitoring will consist primarily of quantifying T cells bearing surface NY-ESO-1 TCR|Objective response|Persistence of TCR gene transduced cells|Time to disease progression","Jonsson Comprehensive Cancer Center|California Institute for Regenerative Medicine (CIRM)","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-000511|NCI-2017-00896|Ribas NYESO SCT Cancer","July 26, 2017","September 1, 2022","September 1, 2023","August 7, 2017",,"October 8, 2021","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03240861"
22,"NCT03506802","TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma","NYSCT MM","Withdrawn","No Results Available","HLA-A*0201 Positive Cells Present|NY-ESO-1 Positive Tumor Cells Present|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Radiation: 18F-FHBG|Biological: Aldesleukin|Biological: Cellular Therapy|Procedure: Computed Tomography|Biological: Filgrastim|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Procedure: Leukapheresis|Drug: Melphalan|Drug: Plerixafor|Procedure: Positron Emission Tomography","Incidence of dose limiting toxicity|Feasibility of NY-ESO-1 TCR transgenic cells|Persistence of transduced T cells|Engraftment and persistence of transduced progeny T cells|Engraftment and persistence of transduced T cells and progeny T cells|Persistence of TCR gene transduced cells|Long term monitoring for replication competence of retrovirus (RCR) and lentivirus (RCL)|Immunological monitoring|Objective response|Duration of overall complete response|Duration of overall response|Time to disease progression","Jonsson Comprehensive Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-001866|NCI-2018-00204","July 10, 2018","June 25, 2019","June 25, 2019","April 24, 2018",,"July 24, 2020","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03506802"
23,"NCT04577326","Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma",,"Recruiting","No Results Available","Malignant Pleural Mesothelioma (MPM)","Drug: cyclophosphamide|Biological: CAR T cells","MTD of M28z1XXPD1DNR|overall response rate (ORR)","Memorial Sloan Kettering Cancer Center|Atara Biotherapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-328","September 30, 2020","September 2023","September 2023","October 6, 2020",,"July 20, 2021","Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04577326"
24,"NCT00794131","Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Cancers (Solid Tumors)","Biological: GL-ONC1","Determine the safety and tolerability of GL-ONC1, administered intravenously to patients with advanced solid tumors.|Detection of virus delivery to primary and/or metastatic tumors by PCR and immunohistochemistry.|Evaluation of anti-vaccinia virus immune response (antibody responses)|Evaluation of viral delivery by fluorescence imaging|Determine recommended dose and schedule for future investigation.|Evaluation of anti-tumor activity|Determine possible predictive value of Circulating Tumor Cell counts and Beta-glucuronidase levels relative to patient survival outcomes.|Assess correlation of CTC number with radiological (imaging) as early pharmacodynamic and response rate indicators for GL-ONC1 treatment.","Genelux Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Genelux - P01","November 2008","November 2015","November 2015","November 19, 2008",,"December 14, 2015","Royal Marsden Hospital, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00794131"
25,"NCT04426669","A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering",,"Recruiting","No Results Available","Gastrointestinal Epithelial Cancer|Gastrointestinal Neoplasms|Cancer of Gastrointestinal Tract|Cancer, Gastrointestinal|Gastrointestinal Cancer|Colo-rectal Cancer|Pancreatic Cancer|Gall Bladder Cancer|Colon Cancer|Esophageal Cancer|Stomach Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Tumor-Infiltrating Lymphocytes (TIL)|Drug: Aldesleukin","Maximum tolerated dose (MTD)|Preliminary efficacy of tumor reactive autologous lymphocytes with knockout of CISH gene in patients with refractory metastatic gastrointestinal epithelial cancers: changes in diameter|Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events|Progression-Free Survival (PFS)|Overall Survival (OS)|Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes","Intima Bioscience, Inc.|Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019LS002","May 15, 2020","October 2022","October 2022","June 11, 2020",,"August 23, 2021","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04426669"
26,"NCT02081937","CART-19 Immunotherapy in Mantle Cell Lymphoma",,"Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer|Non-hodgkin Lymphoma,B Cell|Mantle Cell Lymphoma","Biological: anti-CD19-CAR vector-transduced T cells","Occurrence of study related adverse events|Clinical responses to CART-19 cell therapy","Chinese PLA General Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN301-XYK-CAR001","March 2014","December 2018","December 2019","March 7, 2014",,"March 11, 2014","Department of Hematology of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02081937"
27,"NCT01318317","Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma","Procedure: peripheral blood stem cell transplantation (PBSCT)|Biological: filgrastim|Genetic: polymerase chain reaction|Biological: rituximab|Biological: genetically engineered lymphocyte therapy|Other: laboratory biomarker analysis|Drug: plerixafor|Procedure: autologous hematopoietic stem cell transplantation","MTD based on DLTs and defining the full toxicity profile (Phase I)|Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) detection above background (Phase II)|Rates of engraftment and persistence|Failure to engraft|Progression-free survival|Overall survival","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","57","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09174|NCI-2011-00344|P50CA107399","October 20, 2011","August 2022","August 2022","March 18, 2011",,"September 7, 2020","City of Hope Medical Center, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT01318317"
28,"NCT00621452","Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Biological: aldesleukin|Genetic: polymerase chain reaction|Genetic: gene rearrangement analysis|Procedure: lymph node biopsy|Biological: genetically engineered lymphocyte therapy|Procedure: bone marrow aspiration|Other: flow cytometry|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay","Feasibility of transfecting and expanding the necessary numbers of T cells and the types of problems and toxicities which might be encountered, graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Comparison of the percentages of CD20-specific T cells and malignant B cells present in the blood before and after each T cell infusion|Immune response as assessed by ELISA and percent chromium release in cytotoxicity assays|Absolute numbers of T cells expressing the chimeric T Cell receptor (cTCR) per cubic uL of blood","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 1","12","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2154.00|NCI-2010-00416","August 2007","January 2014",,"February 22, 2008",,"August 6, 2014","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00621452"
29,"NCT03157804","Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A","FANCOLEN-1","Active, not recruiting","No Results Available","Fanconi Anemia","Procedure: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|Biological: Genetically Engineered Hematopoietic Stem/Progenitor Cells|Other: Laboratory Biomarker Analysis|Biological: Filgrastim|Drug: Plerixafor|Procedure: Bone Marrow Aspiration","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells three years after infusion.|Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)|Centro de Investigación en Red de Enfermedades Raras (CIBERER)|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Hospital Vall d'Hebron|Universitat Autonoma de Barcelona","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-006100-12","January 7, 2016","April 23, 2019","April 2022","May 17, 2017",,"November 25, 2020","Hospital Vall d'Hebron, Barcelona, Spain|Hospital Infantil del Niño Jesus, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03157804"
30,"NCT04639245","Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8","Drug: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Biological: PD1 Inhibitor","Incidence of treatment-related unexpected grade 3 or higher adverse events|Best overall response|Peripheral blood concentration of infused transgenic T cells over time|Concentration of transgenic T cells in tumor tissue|Progression-free survival|Overall survival|Objective response rates","Fred Hutchinson Cancer Research Center|SignalOne Bio, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG1007463|NCI-2020-06602|10420","July 19, 2021","December 1, 2024","December 1, 2024","November 20, 2020",,"November 16, 2021","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04639245"
31,"NCT03691376","Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",,"Active, not recruiting","No Results Available","Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Platinum-Sensitive Fallopian Tube Carcinoma|Platinum-Sensitive Ovarian Carcinoma|Platinum-Sensitive Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma","Biological: Aldesleukin|Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Other: Cellular Therapy|Drug: Melphalan","Incidence of adverse events|Maximum tolerated dose (MTD)|Change in Immunological parameters associated with T cell persistence|Tumor response rates to treatment|Progression-free survival|Overall survival|Duration of response|Appearance of target antigen/major histocompatibility complex loss variants upon disease recurrence|Assessment of bioactivity|Assessment of Immunological parameters associated with functionality","Roswell Park Cancer Institute","Female","18 Years and older   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","i 287616|NCI-2018-01758","January 24, 2019","January 30, 2021","June 24, 2022","October 1, 2018",,"May 18, 2021","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03691376"
32,"NCT03017131","Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",,"Active, not recruiting","No Results Available","Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma","Biological: Aldesleukin|Drug: Cyclophosphamide|Drug: Decitabine|Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes|Other: Laboratory Biomarker Analysis","Incidence of adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Appearance of target antigen/major histocompatibility complex loss variants upon disease recurrence|Clinical response rates|Duration of response|Immunological parameters associated with T cell persistence, bioactivity and functionality|Overall survival|Progression free survival","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","i 283616|NCI-2016-01477|P30CA016056|P50CA159981","December 8, 2017","March 23, 2020","March 23, 2032","January 11, 2017",,"May 10, 2021","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03017131"
33,"NCT02456350","Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies",,"Unknown status","No Results Available","Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia|Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR transduced T cells","Number of participants with Adverse Events|Number of participants with Clinical responses","Shenzhen Second People's Hospital|Shenzhen Institute for Innovation and Translational Medicine","All","1 Year to 85 Years   (Child, Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201504001","April 2015","December 2019","December 2019","May 28, 2015",,"August 3, 2016","Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02456350"
34,"NCT03744910","Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients","IMAGINE","Recruiting","No Results Available","Antibody-mediated Rejection","Biological: Clazakizumab|Drug: Physiologic saline solution","Time to all-cause composite allograft loss|Incidence and time to death-censored allograft loss|Change in mean estimated glomerular filtration rate (eGFR) from Baseline to End of Treatment (EOT)|Change in spot urine albumin creatinine ratio (UACR) from Baseline to EOT|Change in (Donor-specific antibodies) DSA titers and Mean fluorescence intensity (MFI) scores from Baseline to EOT|Incidence of acute rejection episodes of T cell-mediated rejection(TCMR) and Antibody-mediated rejection (ABMR) from Baseline to EOT|Change in Banff lesion grading score (2015 criteria) of pre-treatment to post-treatment (Week 52) kidney biopsies|Overall patient survival|Maximum serum concentration (Cmax, Cmax ss) of CSL300|Trough serum concentrations (Ctrough, Ctrough ss) of CSL300|Area under the concentration-time curve (AUC0-tau) at steady state of CSL300|Time of maximum serum concentration (Tmax, Tmax ss) of CSL300","CSL Behring|ICON Clinical Research","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSL300_3001|2018-003682-34|VKTX01","October 14, 2019","June 2028","November 2028","November 19, 2018",,"February 21, 2021","Mayo Clinic Hospital, Phoenix, Arizona, United States|California Institute of Renal Research, San Diego, California, United States|NU Comprehensive Transplant Center, Chicago, Illinois, United States|Maine Medical Center/ Maine Medical Center Research Institute, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Central Pennsylvania Transplant Foundation, Harrisburg, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt Nephrology Clinical Trials, Nashville, Tennessee, United States|Renal Disease Research Institute, Dallas, Texas, United States|VCU Health, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States|Providence Medical Research Center, Spokane, Washington, United States|University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|WSLHD, Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Health Monash Medical Centre, Clayton, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Vancouver General Hospital - Gordon & Leslie Diamond Centre, Vancouver, British Columbia, Canada|St. Paul's Hospital, Providence Health Care, Univ. Of British Columbia, Vancouver, British Columbia, Canada|Shared Health Inc. operating as the Health Sciences Centre, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Royal Victoria Hospital, Montréal, Quebec, Canada|St Paul's Hospital Foundation, Saskatoon, Saskatchewan, Canada|IKEM, Prague, Czechia|CHU GRENOBLE ALPES - Consultation Néphrologie Bureau des ARC (Côté Chartreuse, Rez-de-Chaussée Haut), Grenoble, Grenoble Cédex 09, France|Néphrologie - Pavillon Sainte Venise - CHU de Rouen - Hôpital de Bois Guillaume, Bois-Guillaume, France|Hopital Edouard Herriot, Lyon, France|Hopital Necker Enfants Malades, Paris, France|CHU Rangueil, Toulouse, France|Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM), Berlin, Germany|Debreceni Egyetem, Klinikai Központ, Auguszta, Debrecen, Hungary|University of Szeged, Szeged, Hungary|Radboudumc, Nijmegen, Gelderland, Netherlands|Amsterdam UMC location AMC, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|UMCUtrecht, Utrecht, Netherlands|Hospital Del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT03744910"
35,"NCT00939068","Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission",,"Unknown status","No Results Available","Chronic Hepatitis B, Gestation","Drug: Telbivudine|Biological: engineered HB vaccine","the intrauterine transmission rate;vertical transmission rate (intrauterine and delivery)|liver function normalization rate; HBV DNA and HBeAg reduction and negative conversion rate;|drug adverse reaction in pregnant women; complications during pregnancy and delivery, gestational age at delivery, the method of delivery, peripartum hemorrhage, the newborn growth and development milestones, Apgar score, newborn deformity prevalence","Southeast University, China","Female","20 Years to 40 Years   (Adult)","Phase 4","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H200804","February 2008","July 2010","November 2010","July 14, 2009",,"October 14, 2009",,,"https://ClinicalTrials.gov/show/NCT00939068"
36,"NCT03969641","Safety of RIV4 Versus IIV4 in Pregnant Women",,"Completed","No Results Available","Safety|Adverse Event Following Immunisation|Birth Outcomes","Biological: Quadrivalent Recombinant Influenza Vaccine|Biological: Quadrivalent Inactivated Influenza Vaccine","Adverse birth outcomes in pregnant women vaccinated with RIV4 versus IIV4|Preterm birth after RIV4 versus IIV4 vaccination|Combined fetal and neonatal death after RIV4 versus IIV4 vaccination|Spontaneous abortion after RIV4 versus IIV4 vaccination|Pregnant women with moderate/severe solicited reactogenicity events (local and systemic) within 8 days after vaccination with RIV4 versus IIV4","Duke University|Children's Hospital Medical Center, Cincinnati|Boston Medical Center|Centers for Disease Control and Prevention","Female","18 Years and older   (Adult, Older Adult)","Phase 4","383","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Pro00101707","September 5, 2019","September 29, 2021","September 29, 2021","May 31, 2019",,"November 4, 2021","Boston Medical Center, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03969641/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03969641"
37,"NCT05095441","A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma",,"Not yet recruiting","No Results Available","Solid Tumor|Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain","Biological: C5252","Evaluate the safety and tolerability of C5252|Characterize Dose Limiting Toxicities|Identify the maximum tolerated dose (MTD) and/or the RD of C5252|Evaluate the PK of C5252|Evaluate the viral shedding of C5252|Overall response rate (ORR)|Progression-free survival (PFS)|Overall Survival (OS)","ImmVira Pharma Co. Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MVR-C5252-001","December 31, 2021","April 30, 2023","April 30, 2026","October 27, 2021",,"October 27, 2021",,,"https://ClinicalTrials.gov/show/NCT05095441"
38,"NCT03152318","A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","rQNestin","Recruiting","No Results Available","Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic/Pylomyxoid Astrocytoma|Brain Tumor|Glioma|Brain Cancer|Glioblastoma|Glioblastoma Multiforme","Drug: rQNestin|Drug: Cyclophosphamide|Procedure: Stereotactic biopsy","Maximum Tolerated Dose|MRI Changes in Permeability|MRI Changes in Volume|MRI Changes in Flow|Viral Shedding in Saliva|HSV1 Viremia|HSV1 Antibody Response","Dana-Farber Cancer Institute|National Institutes of Health (NIH)|Candel Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","56","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-557","July 18, 2017","December 2022","December 2023","May 15, 2017",,"August 11, 2021","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03152318"
39,"NCT05084430","A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)",,"Not yet recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma|Gliosarcoma","Drug: M032 & Prembrolizumab","Overall Survival at 12 and 24 months and Progression Free Survival at 6 months (PFS-6)|Overall Survival (OS) and Progression Free Survival (PFS)","University of Alabama at Birmingham|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300007756","December 20, 2021","December 20, 2023","December 20, 2024","October 19, 2021",,"October 19, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT05084430"
40,"NCT03132922","MAGE-A4ᶜ¹º³²T for Multi-Tumor",,"Active, not recruiting","No Results Available","Urinary Bladder Cancer|Melanoma|Head and Neck Cancer|Ovarian Cancer|Non-Small Cell Lung Cancer|Esophageal Cancer|Gastric Cancer|Synovial Sarcoma|Myxoid Round Cell Liposarcoma|Gastroesophageal Junction","Genetic: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Radiation: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation","Number of subjects with adverse events (AE), including serious adverse events (SAEs).|Determining dose limiting toxicities (DLT) and optimally tolerated dose range|Evaluation of persistence of genetically modified T cells.|Measurement of RCL in genetically modified T cells.|Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).|Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.|Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.|Interval between the date of first documented evidence of stable disease (SD) until first documented disease progression or death due to any cause.|Interval between the date of first T cell infusion and the earliest date of disease, progression or death due to any cause|Interval between the date of first T cell infusion and date of death due to any cause.|Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)","Adaptimmune","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADP-0044-001","July 5, 2017","September 2032","September 2035","April 28, 2017",,"October 5, 2021","University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University Medical Center, Duke Cancer Institute, Durham, North Carolina, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology - Sarah Cannon Research Institute, Nashville, Tennessee, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03132922"
41,"NCT02989064","MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",,"Completed","No Results Available","Urothelial Carcinoma|Head and Neck Cancer|Melanoma|Bladder Urothelial Carcinoma","Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells","Number of subjects with adverse events (AE), including serious adverse events (SAE).|Evaluation of the persistence of genetically modified T cells|Measurement of RCL in genetically modified T cells.|Assessment of dose limiting toxicities to determine optimally tolerated dose range|Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).|Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.|Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.|Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause.|Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause|Interval between the date of first T cell infusion and date of death due to any cause.|Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)","Adaptimmune","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADP-0022-004","October 2016","December 18, 2019","June 4, 2020","December 12, 2016",,"December 19, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University - School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology - Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Start Madrid-FJD, Fundación Jimѐnez Díaz, Madrid, Spain|Hospital Universitario 12 Octubre Avda. de Córdoba, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02989064"
42,"NCT04792489","DALY 2.0 USA/ MB-CART2019.1 for DLBCL",,"Recruiting","No Results Available","DLBCL","Biological: MB-CART2019.1","Overall Response Rate|Complete Response Rate|Duration of Response|Best Overall Response|Progression Free Survival|Overall Survival|Pharmacokinetics of MB-CART2019.1 [Maximum concentration (Cmax)]|Pharmacokinetics of MB-CART2019.1 [Time to maximum concentration (Tmax)]|Pharmacokinetics of MB-CART2019.1 [Area under the curve (AUC)]","Miltenyi Biomedicine GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M-2018-344","May 25, 2021","May 30, 2022","April 30, 2024","March 11, 2021",,"July 14, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Stanford University, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04792489"
43,"NCT02923466","Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors",,"Active, not recruiting","No Results Available","Malignant Solid Tumour","Biological: VSV-IFNβ-NIS|Biological: VSV-IFNβ-NIS and avelumab","Maximum Tolerated Dose (MTD) of VSV-IFNβ-NIS Monotherapy and Combination Therapy","Vyriad, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VYR-VSV2-101","April 17, 2017","February 2022","December 2022","October 4, 2016",,"July 7, 2021","University of Miami, Miami, Florida, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Sanford Cancer Center, Sioux Falls, South Dakota, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02923466"
44,"NCT04194190","A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL",,"No longer available","No Results Available",,"Drug: Individual Patient TCR-Transduced PBL",,"National Institutes of Health Clinical Center (CC)",,"Child, Adult, Older Adult",,,"NIH","Expanded Access:Individual Patients",,"20-C-9956|209956",,,,"December 11, 2019",,"September 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04194190"
45,"NCT03017820","VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma",,"Recruiting","No Results Available","Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Plasma Cell Myeloma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Acute Myeloid Leukemia|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Plasma Cell Myeloma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma","Procedure: Computed Tomography|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Drug: Ruxolitinib Phosphate|Procedure: Single Photon Emission Computed Tomography","Incidence of adverse events of grade 3 or higher|Clinical response|Progression-free survival|Overall survival","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","65","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1684|NCI-2017-00049|P30CA015083","April 4, 2017","December 29, 2021","December 29, 2021","January 11, 2017",,"September 27, 2021","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03017820"
46,"NCT02700230","Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery",,"Recruiting","No Results Available","Metastatic Malignant Peripheral Nerve Sheath Tumor|Neurofibromatosis Type 1|Recurrent Malignant Peripheral Nerve Sheath Tumor","Procedure: Computed Tomography|Other: Laboratory Biomarker Analysis|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Other: Quality-of-Life Assessment|Procedure: Single Photon Emission Computed Tomography","Best response using the World Health Organization response criteria|Incidence of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Maximum tolerated dose defined as the highest safely tolerated dose level where at most 1 out of 6 patients experience dose-limiting toxicity (DLT) with the next higher dose having at least 2 patients out of a maximum of 6 patients experience DLT|Absolute percentage change in quality of life measured using the Brief Pain Inventory (short form) and Brief Fatigue Inventory|Change in biodistribution of virally infected cells at various time points after infection with MV-NIS using single photon emission computed tomography/computed tomography|Growth-rate between treated and untreated lesions|Humoral and cellular immune response to the injected virus|Incidence of measles virus shedding/persistence following intratumoral administration|Incidence of viral replication following intratumoral administration|Incidence of viremia following intratumoral administration|Progression-free survival by radiographic response of the treated lesion using World Health Organization response criteria guidelines|Time to progression|Time until hematologic nadirs (absolute neutrophil count, platelets, hemoglobin)|Viral gene expression|Virus elimination as monitored by single photon emission computed tomography/computed tomography imaging","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1372|NCI-2016-00179|P30CA015083","December 8, 2017","June 15, 2022","June 15, 2022","March 7, 2016",,"June 18, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02700230"
47,"NCT03120624","VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer",,"Recruiting","No Results Available","Metastatic Endometrial Carcinoma|Recurrent Endometrial Adenocarcinoma|Recurrent Endometrial Carcinoma|Recurrent Endometrial Clear Cell Adenocarcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Mixed Cell Adenocarcinoma|Recurrent Endometrial Serous Adenocarcinoma|Recurrent Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinosarcoma|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7","Procedure: Biopsy|Procedure: Computed Tomography|Other: Fluorine F 18 Tetrafluoroborate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Procedure: Planar Imaging|Procedure: Positron Emission Tomography|Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Drug: Ruxolitinib|Drug: Ruxolitinib Phosphate|Procedure: Single Photon Emission Computed Tomography|Drug: Technetium Tc-99m Sodium Pertechnetate","Maximum tolerated dose of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib phosphate)|Incidence of adverse events|Number of clinical responses|Viral replication and shedding in blood, throat washings, urine, and buccal swabs assessed via quantitative reverse transcriptase polymerase chain reaction|Biodistribution and kinetics of virus spread and NIS gene expression in vivo|Time until treatment related grade 3+ toxicity|Time until hematologic nadirs (white blood cells, absolute neutrophil count, platelets)","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","77","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1562|NCI-2017-00615|P30CA015083","September 15, 2017","June 1, 2023","July 15, 2023","April 19, 2017",,"July 28, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03120624"
48,"NCT01236573","Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes",,"Terminated","Has Results","Skin Cancer|Metastatic Melanoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: IL-12 transduced TIL","Maximum Tolerated Dose (MTD)|Response (Complete Response (CR) + Partial Response (PR)) to Therapy|Number of Participants With Adverse Events","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years to 66 Years   (Adult, Older Adult)","Phase 1|Phase 2","34","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110011|11-C-0011","October 2010","March 2015","March 2015","November 7, 2010","October 26, 2015","November 26, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01236573"
49,"NCT02364713","MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer",,"Recruiting","No Results Available","Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Primary Peritoneal Carcinosarcoma|Primary Peritoneal Clear Cell Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Primary Peritoneal Transitional Cell Carcinoma|Primary Peritoneal Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma","Biological: Bevacizumab|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Drug: Paclitaxel|Drug: Pegylated Liposomal Doxorubicin Hydrochloride|Other: Quality-of-Life Assessment|Drug: Topotecan Hydrochloride","Overall survival|Progression-free survival|Objective response rates defined to be a complete response or partial response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart|Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.0|Quality of life as measured by the Functional Assessment of Cancer Therapy-Ovarian questionnaire","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1365|NCI-2015-00133|P30CA015083","March 13, 2015","March 1, 2022","March 28, 2024","February 18, 2015",,"April 8, 2021","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02364713"
50,"NCT00157703","G207 Followed by Radiation Therapy in Malignant Glioma",,"Completed","No Results Available","Malignant Glioma","Drug: G207","Adverse events|Radiographic response|Performance scale|Overall survival|Immune response|Presence of G207 in blood and saliva","MediGene|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Phase 1","9","Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT2001","May 2005","October 2008","December 2008","September 12, 2005",,"December 16, 2008","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00157703"
51,"NCT02192775","UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus",,"Completed","Has Results","Multiple Myeloma","Drug: MV-NIS","The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines","University of Arkansas","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","203081","March 2015","August 20, 2019","August 20, 2019","July 17, 2014","October 19, 2020","October 19, 2020","University of Arkansas for Medical Science, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02192775/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02192775"
52,"NCT00456664","CMV Disease and IRIS in HIV-1 Infected Persons",,"Completed","No Results Available","HIV Infections|Cytomegalovirus","Genetic: IE gene",,"Kaohsiung Medical University Chung-Ho Memorial Hospital","All","Child, Adult, Older Adult",,"200","Other","Observational",,"QM094007","November 2006","July 2008","July 2008","April 5, 2007",,"February 3, 2009","Kaoshing Medical University Chung-Ho Memorial Hospital, Kaoshiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00456664"
53,"NCT03168438","Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma",,"Terminated","No Results Available","Neoplasms","Drug: Letetresgene autoleucel|Drug: Letetresgene autoleucel with pembrolizumab|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Pembrolizumab","Number of participants with adverse events (AEs)and serious adverse events (SAEs)|Number of participants with abnormal laboratory paramaters|Number of participants with abnormal cardiac assessments by electrocardiogram (ECG)|Overall Response Rate (ORR)|Time to Response (TTR)|Duration of Response (DOR) for all participants who achieve at least PR|Progression-free survival (PFS)|Maximum persistence (Cmax)|Time to Cmax (Tmax)|Area under the time curve from zero to time t (AUC 0-t)","GlaxoSmithKline|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","208470|ADP-0011-008|KEYNOTE-487","August 18, 2017","July 13, 2020","November 5, 2020","May 30, 2017",,"February 25, 2021","GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03168438"
54,"NCT02068794","MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer",,"Recruiting","No Results Available","Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma","Other: Laboratory Biomarker Analysis|Procedure: Mesenchymal Stem Cell Transplantation|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter","Maximum tolerated dose (MTD) (Phase I)|Number and severity of adverse events (Phase I)|Overall toxicity incidence (Phase I)|Toxicity profiles by dose level and patient (Phase I)|Proportion of patients alive at 12 months (Phase II)|Tumor response (Phase II)|Rate of progression free survival (Phase II)|Overall survival (Phase II)|Progression free survival (Phase II)|Maximum grade for each type of toxicity (Phase II)","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","57","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1266|NCI-2014-00016|P30CA015083|P50CA136393|P50CA083639","March 31, 2014","March 1, 2022","March 1, 2022","February 21, 2014",,"April 8, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02068794"
55,"NCT01846091","Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer",,"Active, not recruiting","No Results Available","Estrogen Receptor Negative|Estrogen Receptor Positive|Head and Neck Squamous Cell Carcinoma|HER2/Neu Negative|HER2/Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Head and Neck Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma","Other: Laboratory Biomarker Analysis|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter","MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) as assessed by the National Cancer (NCI) CTCAE v. 4.0|Number of toxicity incidents defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment|Number of responses using Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1|Time to tumor progression","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC0979|NCI-2013-00811|P30CA015083","April 2013","September 18, 2019","December 31, 2021","May 3, 2013",,"February 25, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01846091"
56,"NCT00450814","Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma",,"Completed","Has Results","Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Other: Pharmacological Study","Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)|Maximum Tolerated Dose (MTD) (Phase I)|Proportion of Confirmed Response, Defined as a Partial Response (PR) or Better (Phase II)|Overall Toxicity Rate, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) (Phase I)|Number of Patients With Clinical Responses (Phase I)|Overall Survival (Phase II)|Time to Progression (TTP) (Phase II)|Progression-free Survival (Phase II)|Failure-free Survival (Phase II)|Overall Toxicity Rate, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) (Phase II)","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC038C|NCI-2009-01194|P30CA015083|R01CA125614|R01CA168719","November 30, 2006","July 10, 2018","November 20, 2019","March 22, 2007","December 16, 2019","December 16, 2019","Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT00450814/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00450814"
57,"NCT00408590","Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer",,"Completed","Has Results","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Biological: carcinoembryonic antigen-expressing measles virus|Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis","Dose Limiting Toxicity|Number of Responses (Complete and Partial, Stable and Progressive Disease)|Change in CA-125 Levels From Baseline to Last Recorded Value (up to 18 Months)|Time to Progression","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","37","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000515008|P30CA015083|MC0117|1260-03|NCI-2009-01199","April 19, 2004","August 2012","November 7, 2017","December 7, 2006","October 2, 2017","March 1, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00408590"
58,"NCT00028158","Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer",,"Completed","No Results Available","Glioma|Astrocytoma|Glioblastoma","Drug: G207, an oncolytic virus",,"MediGene","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NG1-003","December 2001",,"October 2003","December 18, 2001",,"June 24, 2005",,,"https://ClinicalTrials.gov/show/NCT00028158"
59,"NCT00095862","Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers",,"Terminated","No Results Available","Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: allogeneic GM-CSF-secreting breast cancer vaccine|Biological: recombinant interferon alfa|Drug: cyclophosphamide","Safety, tolerability, and feasibility|Clinical response|Time to progression|Survival|Correlation of clinical response with immunological response","Wiseman Research Initiatives LLC|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000393552|WRI-GEV-007","November 2004",,,"November 9, 2004",,"February 5, 2018","Glendale Memorial Hospital Comprehensive Cancer Center, Glendale, California, United States|Hollywood Presbyterian Medical Center, Los Angeles, California, United States|Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00095862"
60,"NCT00012155","Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver",,"Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: NV1020",,"Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1",,"Other|NIH","Interventional","Primary Purpose: Treatment","MSKCC-00022|CDR0000068488|MGENE-NR1-001|NCI-G01-1920","October 2000","November 2002","December 2009","June 9, 2003",,"June 26, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00012155"
61,"NCT03854630","Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection",,"Recruiting","No Results Available","Viral Hepatitis B|Immunization; Infection|HIV Infections","Drug: Engerix-B","Vaccine efficacy|High-titer response|Long-term efficacy|Long-term high-titer response|Hepatitis B incident infection rate|Hepatitis C infection and syphilis infection rate|HIV seroconversion among HIV-negative MSM","National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan","Male","20 Years and older   (Adult, Older Adult)","Phase 4","575","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201608051MIPC","September 6, 2017","June 1, 2023","December 31, 2023","February 26, 2019",,"May 22, 2020","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03854630"
62,"NCT04188223","Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children",,"Completed","No Results Available","Hepatitis B","Biological: Recombinant Hepatitis B (Bio Farma) Vaccine|Biological: Recombinant Hepatitis B (Bio Farma) Vaccine®","Number of subjects with Immediate reaction|percentage of subjects with Immediate reaction|Number of subjects with Adverse Events from 1 day to 28 days after vaccination|Percentage of subjects with Adverse Events from 1 day to 28 days after vaccination|Number of subjects with Serious Adverse Events from 1 day to 28 days after vaccination|Percentage of subjects with serious Adverse Events from 1 day to 28 days after vaccination|Number of Lab Deviation for adults subjects in 7 days of immunization|Safety Comparison between each intervention group|Protectivity of Hepatitis B vaccine (number of subject with protective anti HbsAg)|Protectivity of Hepatitis B vaccine (4 times increasing antibody)|Protectivity of Hepatitis B vaccine (Geometic Mean Titers)|Anti-HBs description between groups","PT Bio Farma","All","10 Years to 40 Years   (Child, Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Hep B 0119","December 3, 2019","July 16, 2020","July 16, 2020","December 5, 2019",,"July 30, 2020","Hasan Sadikin Hospital, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04188223"
63,"NCT03919578","Protectivity and Safety Following Recombinant Hepatitis B Vaccine",,"Completed","No Results Available","Immunogenicity","Biological: Recombinant Hepatitis B vaccine|Biological: Recombinant Hepatitis B (Bio Farma)","Percentage of subjects with increasing antibody titer >= 4 times|Geometric Mean Titer (GMT)|Percentage of subjects with transition of seronegative to seropositive|Percentage of subjects with at least one immediate reaction|Percentage of subjects with at least one of these adverse events|Serious adverse event after vaccination|Comparison adverse events between Investigational Products (Hepatitis B) and Control|Comparison of adverse events between each lot number of Recombinant Hepatitis B vaccine","PT Bio Farma","All","10 Years to 40 Years   (Child, Adult)","Phase 2|Phase 3","536","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hep B 0218","September 11, 2019","January 30, 2020","February 28, 2020","April 18, 2019",,"April 1, 2020","RSND, Semarang, Central Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT03919578"
64,"NCT04887025","Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma",,"Not yet recruiting","No Results Available","Relapsed or Refractory B-cell Lymphoma","Biological: RGV004","To define the Max tolerated dose (MTD) of RGV004|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Objective remission rate (ORR)|RGV004 viral DNA in blood|RGV004 viral shedding in saliva|RGV004 viral shedding in urine","Second Affiliated Hospital, School of Medicine, Zhejiang University|Hangzhou Rongu Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IR2021002042","March 15, 2022","March 15, 2023","March 15, 2025","May 14, 2021",,"September 1, 2021","2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04887025"
65,"NCT01443260","A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis",,"Completed","No Results Available","Peritoneal Carcinomatosis","Biological: GL-ONC1","Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)|Dose Level and Dose Schedule|Detection of Anti-tumor Activity","Genelux GmbH|Genelux Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Genelux - PO2|2010-022680-35","February 2012","September 2014","September 2014","September 29, 2011",,"March 10, 2015","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT01443260"
66,"NCT03790670","Biomarker Assessments of Leukine During Treatment of Parkinson's Disease",,"Recruiting","No Results Available","Parkinson Disease","Drug: sargramostim","Incidence of Treatment-Associated Adverse Events|Determination of Immune Cell Phenotype|Determination of Immune Cell Number|Determination of Immune Cell Function","University of Nebraska","All","35 Years to 85 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","839-18-FB","January 30, 2019","September 30, 2022","December 30, 2022","January 2, 2019",,"October 19, 2020","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03790670"
67,"NCT04903080","HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma",,"Not yet recruiting","No Results Available","Ependymoma","Biological: HER2 Specific CAR T Cell","Number of Subjects with Dose-Limiting Toxicity (DLT) in Phase I Arm|Number of Subjects with Dose-Limiting Toxicity (DLT) in Surgical Arm|Percentage of Subjects whose Treatment Delivery Meets Feasibility Criteria|Expansion and Persistence of HER2 CAR T Cells at First Infusion in patients who received this treatment|Expansion and Persistence of HER2 CAR T Cells at Second Infusion in patients who received this treatment|Expansion and Persistence of HER2 CAR T Cells at Third Infusion in patients who received this treatment|Presence of intra-tumoral HER2 CAR T Cells following First Infusion in Surgical Arm|Presence of HER2 CAR T Cells following Second Infusion in Surgical Arm|Presence of HER2 CAR T Cells following Third Infusion in Surgical Arm|Best antitumor Response of Infused HER2 CAR T Cells in Phase I Arm|Best Antitumor Response of Infused HER2 CAR T Cells in Surgical Arm|Event-free Survival (EFS)|Overall Survival (OS)","Pediatric Brain Tumor Consortium|Texas Children's Cancer Center|Baylor College of Medicine","All","1 Year to 22 Years   (Child, Adult)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBTC-059","September 3, 2021","July 3, 2025","July 3, 2040","May 26, 2021",,"September 9, 2021",,,"https://ClinicalTrials.gov/show/NCT04903080"
68,"NCT02687724","Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis","GOAL-ARC","Unknown status","No Results Available","Colitis","Drug: Golimumab (GLM)","Patient Continuous Clinical Response (pCCR)|Total Mayo Score|Partial Mayo Score|Modified Partial Mayo Score|Week 14 Clinical Response|Clinical Remission|Clinical Flare|Corticosteroid Free Remission|Mucosal healing","University College Dublin","All","18 Years and older   (Adult, Older Adult)","Phase 4","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCRC/15/007","June 2016","February 2020","February 2020","February 22, 2016",,"July 19, 2018","St Vincent's University Hospital, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT02687724"
69,"NCT02706119","Insulin in Total Parenteral Nutrition","INSUPAR","Completed","No Results Available","Diabetes Mellitus","Drug: Subcutaneous glargine insulin|Drug: Regular insulin added to TPN bag","Basal blood glucose value before starting TPN|Periodical blood glucose|Variation of average blood glucose compared with total dose of insulin|Number of hypoglycaemia|Number of severe hypoglycaemia|Hypoglycemia blood glucose values|Hypoglycemia symptoms|Standard deviation of blood glucose|Blood glucose coefficient of variation (CV)","Fundación Pública Andaluza Progreso y Salud|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 4","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","FPS-INSUPAR-2015-01","July 1, 2016","March 31, 2018","April 4, 2018","March 11, 2016",,"May 24, 2018","Hospital Arquitecto Marcide-Naval, Ferrol, A Coruña, Spain|Hospital de Cabueñes, Gijón, Asturias, Spain|Hospital de Mérida, Mérida, Badajoz, Spain|Hospital Son Llátzer, Palma de Mallorca, Baleares, Spain|Hospital General Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain|Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Infanta Cristina, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Bellvitge, Barcelona, Spain|Hospital de Sant Joan Despi Moisès Broggi (Consorci Sanitari Integral), Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02706119"
70,"NCT02759588","GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer",,"Active, not recruiting","No Results Available","Ovarian Cancer|Peritoneal Carcinomatosis|Fallopian Tube Cancer","Biological: GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab","Incidence of Treatment-emergent Adverse Events [Safety and Tolerability] (Phase 1b)|Determine Progression-free Survival following Treatment (Phase 2)|Tumor Marker Cancer Antigen-125 (CA-125) (Phase 2)|Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)|Evaluation of Tumor Response to Treatment (Phase 1b)|Evaluation of Immune-related Tumor Response|CA-125 Response (Phase 1b)|Determine Progression-free Survival following Treatment (Phase 1b)|Overall Survival|Clinical Benefit Rate","Genelux Corporation","Female","21 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","64","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GL-ONC1-015","May 2016","December 31, 2020","May 2022","May 3, 2016",,"January 19, 2021","Gynecologic Oncology Associates, Newport Beach, California, United States|AdventHealth Cancer Institute, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02759588"
71,"NCT02315599","Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials",,"Enrolling by invitation","No Results Available","Pediatric Cancers|Hematologic Malignancies|Solid Tumors",,"Conduct long term safety evaluations after gene therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 99 Years   (Child, Adult, Older Adult)",,"500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","150028|15-C-0028","December 23, 2014","April 1, 2035","August 1, 2050","December 12, 2014",,"September 5, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02315599"
72,"NCT03193775","Impact of Hepatitis B Vaccination on HBs Antigenemia",,"Completed","No Results Available","HBV","Biological: HBV vaccine","production of protective HBsAb|impact on Insulin resistance, fibrosis regression","Zagazig University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3777","August 1, 2011","October 1, 2015","October 1, 2015","June 21, 2017",,"June 21, 2017",,,"https://ClinicalTrials.gov/show/NCT03193775"
73,"NCT01263379","Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa",,"Active, not recruiting","No Results Available","Epidermolysis Bullosa Dystrophica|Epidermolysis Bullosa","Biological: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","Percentage surface area of wound healing|Investigator's assessment of graft|duration of type VII collagen production","Stanford University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Abeona Therapeutics, Inc","All","13 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-10202010-7130|IND# 13708|R01AR055914|RAC Protocol # 0701-827|eProtocol 14563","October 5, 2010","December 31, 2023","December 31, 2025","December 20, 2010",,"October 27, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01263379"
74,"NCT04456959","InO - A Retrospective Study of UK Patients With Leukaemia","InO","Completed","No Results Available","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Drug: Inotuzumab Ozogamicin","Clinical characteristics|Duration of treatment with InO|Number of cycles of InO|Interrupted cycles of InO, including reasons (liver toxicity TRAEs, other AEs, tolerance, treatment failure, and course complete).|Doses of InO prescribed|Modification of doses of InO, including reasons (liver toxicity TRAEs, other AEs, tolerance, treatment failure, and course complete).|Azole antifungal therapy concomitant to InO treatment|CR, CRi and CR/CRi response rates by the end of InO treatment, overall and according to the number of salvage therapies in the pre-index observation period (0, 1, ≥2);|Median time to CR/CRi (95% CI)|Number and proportion of patients achieving MRD negativity overall and by the number of completed cycles of InO (after 1, 2, ≥3 cycles of InO) in patients evaluated by flow-cytometry/ molecular assessment / both.|The number and proportion of patients surviving at 3, 6 and 12 months after InO initiation|Cause of death|Median OS (95% CI)|The number and proportion of patients who are relapse-free at 3, 6 and 12 months after InO initiation; Median RFS (95% CI) In patients undergoing follow-up HSCT; Median NRM (95% CI) from the date of follow-up HSCT|Median RFS (95% CI)|In patients undergoing follow-up HSCT; Median NRM (95% CI) from the date of follow-up HSCT|Document and report the number of patients who have received post-InO treatment including: new chemotherapy (blinatumomab, other), HSCT, CAR T cell therapy.|In those who received post InO treatment recorded response to treatment and survival|Incidence of grade 3/4 treatment-related adverse events (lung/cardiac/kidney) following InO initiation in all patients|Incidence of liver dysfunction following InO initiation in all patients","Pfizer","All","18 Years and older   (Adult, Older Adult)",,"28","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","X9001222","January 6, 2020","January 27, 2021","January 27, 2021","July 7, 2020",,"September 9, 2021","University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|University College London Hospital NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust of Fulham Road, London, United Kingdom|Taunton and Somerset NHS Foundation Trust of Musgrove Park Hospital, Taunton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04456959"
75,"NCT01331018","Gene Therapy for Fanconi Anemia",,"Active, not recruiting","No Results Available","Fanconi Anemia","Procedure: Bone Marrow Aspiration|Biological: Filgrastim|Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Drug: Methylprednisolone|Drug: Plerixafor|Drug: Prednisone","Toxicity of gene transfer|Hematological and non-hematological organ toxicity|Development of insertional mutagenesis or hematologic malignancy|Development of replication competent lentivirus|Efficacy of G-CSF and plerixafor mobilization in Fanconi anemia (FA) patients|Efficacy of lineage depletion of bone marrow or mobilized cell product|Transduction efficiency|Detectable levels of transduced cells in blood and marrow|Improved blood counts|Demonstrable functional expression by growth of recipient cells in mitomycin C","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|Rocket Pharma Limited","All","4 Years and older   (Child, Adult, Older Adult)","Phase 1","3","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2097.00|NCI-2011-00202|RG9212015","February 22, 2012","July 17, 2032","July 17, 2032","April 7, 2011",,"June 24, 2021","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01331018"
76,"NCT01584284","Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer",,"Completed","No Results Available","Cancer of Head and Neck","Biological: GL-ONC1","Safety and Tolerability as measured by the number of patients with Adverse Events, as well as type of AE and frequency|Presence of Virus in Tumor|Determine Initial Susceptibility of tumor to viral infection|Anti-Tumor Activity (Early Efficacy)","Genelux Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GL-ONC1-005","April 2012","June 2015","July 2015","April 24, 2012",,"August 25, 2015","Moores UC San Diego Cancer Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01584284"
77,"NCT00104091","Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors",,"Completed","No Results Available","Glioblastoma Multiforme","Drug: TP-38","Evaluate TP-38 at a 100 nanograms/mL concentration for sufficient activity|Efficacy parameters including time to progression, safety, and survival","Teva Branded Pharmaceutical Products R&D, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IXR-202-22-188","December 2004","April 2007","June 2007","February 23, 2005",,"May 23, 2011",,,"https://ClinicalTrials.gov/show/NCT00104091"
78,"NCT05061537","Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",,"Recruiting","No Results Available","Renal Cell Cancer|Melanoma|Non-Small-Cell Lung Cancer|Hepatocellular Cancer|Bladder Cancer|Sarcoma|Head and Neck Cancer|Colorectal Cancer|Ovarian Cancer|Squamous Cell Carcinoma","Biological: PF-07263689|Biological: Sasanlimab","Number of participants with dose limiting toxicities (DLTs) in Dose escalation (Part 1A and 1B)|Number of participants with adverse events|Number of participants with clinically significant laboratory abnormalities|Objective response rate in the dose expansion (Part 2) arms|Objective response rate in dose escalation (Part 1A and 1B)|Maximum concentration (Cmax) of viral load titer of PF-07263689|Time to maximal plasma concentration (Tmax) of viral load titer after PF-07263689 dosing|Area under the Curve from time 0 to the last measurable timepoint (AUClast) of viral load titer after PF-07263689 dosing|Viral titers for vector shedding of PF-07263689 in saliva, urine, injection site swab, and swab from any spontaneous skin pox lesion|Sasanlimab trough concentration (Part 1B and 2)|Incidence and titers of anti-IL2 antibodies and anti-drug antibody (ADA) against PF-07263689 and sasanlimab as applicable|Anti-tumor activity (Part 2)|Overall survival (Part 2)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C4651001|OBIR-2","October 20, 2021","July 6, 2024","July 6, 2024","September 29, 2021",,"November 8, 2021","City of Hope, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT05061537"
79,"NCT02651168","Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study",,"Unknown status","No Results Available","Diabetic Macular Edema","Biological: aflibercept","Change in cytokine levels (picograms per mL) in patients with DME who were previously non-responders to ranibizumab (non-responders) between baseline aflibercept injection.|Relation of baseline aqueous cytokine levels in patients with DME who were previously non-responders to ranibizumab (non-responders) to baseline Snellen BCVA in response to aflibercept","Unity Health Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Protocol B SMH Aflibercept","March 2016","March 2018","June 2018","January 8, 2016",,"January 8, 2016",,,"https://ClinicalTrials.gov/show/NCT02651168"
80,"NCT03048253","A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c",,"Unknown status","No Results Available","Melanoma","Biological: OrienX010","change of tumor size","OrienGene Biotechnology Ltd.","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OrienX010-II-10","March 29, 2016","October 10, 2017","October 28, 2019","February 9, 2017",,"October 2, 2017","Beijing cancer hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03048253"
81,"NCT03456908","F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies",,"Completed","No Results Available","Myeloma Before MV-NIS Treatment|Endometrial Cancer Before VSV-hINF-NIS Treatment","Combination Product: 18F-TFB-PET","Evaluate the uptake and distribution of the imaging agent 18F-TFB|Imaging Sensitivities","Mayo Clinic","All","21 Years and older   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","F18 17-008847","March 16, 2018","December 31, 2019","December 31, 2019","March 7, 2018",,"September 16, 2020","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03456908"
82,"NCT03679455","A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1","OBI-1","Recruiting","No Results Available","Waldenstrom Macroglobulinemia","Drug: Obinutuzumab 25 MG/ML","Best Overall Response (BOR)|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)","Polish Myeloma Consortium|Roche Pharma AG|Bioscience, S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML39235","September 21, 2018","April 2019","December 2022","September 20, 2018",,"November 13, 2018","Uniwersytecki Szpital kliniczy im. Jana Mikulicza-Radeckiego we Wrocławiu; Klinika Hematologii, Nowotworów Krwi Transplantacji Szpiku, Wrocław, Dolnośląskie, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku, Poznań, Wielkopolskie, Poland",,"https://ClinicalTrials.gov/show/NCT03679455"
83,"NCT04196855","Study of Teriparatide in Stress Fracture Healing","RETURN","Recruiting","No Results Available","Stress Fracture|Parathyroid Hormone","Drug: Teriparatide","Radiological healing.|Radiological Healing|Time from randomisation to assessed as 'Clinically Healed'.|Time to 'Healing' as a composite assessment.|Time from randomisation to discharge from rehabilitation.|Pain symptoms on a visual analogue pain scale.|Difference in Quality of life|Adverse events","University of East Anglia|Ministry of Defence, United Kingdom|Darlington Memorial Hospital|Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)","All","18 Years to 40 Years   (Adult)","Phase 3","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","19/HRA/6011","December 23, 2019","June 2022","October 2022","December 12, 2019",,"November 4, 2020","Darlington Memorial Hospital, Darlington, County Durham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04196855"
84,"NCT04373941","Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia","BA_GCSF2b","Recruiting","No Results Available","Biliary Atresia","Drug: Filgrastim","GCSF Response on Bile flow (KBA)|GCSF Response on transplant-free survival (NoK)|GCSF response on liver function and outcome (KBA)|GCSF response on liver function (NoK)","Holterman, Ai-Xuan, M.D.|T Rose Clinical, Inc.|Big Leap Research","All","up to 180 Days   (Child)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HoltermanA","June 1, 2020","June 30, 2022","October 31, 2024","May 5, 2020",,"May 5, 2020","Aga Khan University, Karachi, Pakistan|Nation Children's Hospital, Hanoi, Dong Da District, Vietnam|Children Hospital 1, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT04373941"
85,"NCT03395028","GCSF Adjunct Therapy for Biliary Atresia","BA_GCSF","Completed","No Results Available","Biliary Atresia","Drug: Granulocyte Colony-Stimulating Factor","Dose determination GCSF","Holterman, Ai-Xuan, M.D.|T. Rose Clinical, Inc., United States|Children's National Health System|Big Leap Research, Vietnam","All","up to 180 Days   (Child)","Early Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CR00005169|IND 119679-0007","January 15, 2018","January 31, 2020","January 31, 2020","January 9, 2018",,"February 17, 2020","Children's National Medical Center, Washington, District of Columbia, United States|National Childrens Hospital, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03395028"
86,"NCT04074746","Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Recurrent Anaplastic Large Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Classic Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Fludarabine Phosphate|Biological: Genetically Engineered Lymphocyte Therapy","Incidence of adverse events|Overall survival|Event-free survival|Overall response rate (ORR)|Complete response (CR) rate|Partial response (PR) rate|Duration of response|Persistence of infused donor AFM13-NK cells|Immune reconstitution studies","M.D. Anderson Cancer Center","All","15 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-1092|NCI-2019-03536","July 18, 2020","April 15, 2023","April 15, 2023","August 30, 2019",,"June 3, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04074746"
87,"NCT04809389","A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19",,"Active, not recruiting","No Results Available","Covid19","Biological: DelNS1-nCoV-RBD LAIV|Biological: Matching placebo","The cumulative incidence of reactogenicity for all the subjects received at least 1 dose of investigational medicinal product (IMP), regardless of whether the subject withdrew early, delayed/missed the second dose or received any antipyretic.|The seroconversion rate for serum RBD-specific binding antibodies for all the subjects received 2 doses of IMP, excluding subjects who missed the second dose, received any COVID-19 vaccine other than the IMPs or had a post-dose COVID-19 infection.","The University of Hong Kong","All","18 Years to 55 Years   (Adult)","Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CTC2038","March 29, 2021","September 2022","September 2022","March 22, 2021",,"September 27, 2021","HKU Phase 1 Clinical Trials Centre, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04809389"
88,"NCT04348916","Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",,"Recruiting","No Results Available","Cancer|Melanoma|Solid Tumor|Squamous Cell Carcinoma of Head and Neck|Breast Cancer|Advanced Solid Tumor|Triple Negative Breast Cancer|Colorectal Carcinoma|Non-melanoma Skin Cancer|Liver Metastases","Biological: ONCR-177|Biological: pembrolizumab","Percentage of Dose-Limiting Toxicities (DLTs)|Percentage of Adverse Events (AEs)|Percentage of Serious Adverse Events (SAEs)|Maximum Tolerated Dose (MTD) of ONCR-177|Recommended Phase 2 Dose (RP2D) of ONCR-177|Percentage of Objective Response Rate (ORR)|Durable Response Rate (DRR)|Progression Free Survival (PFS)|Overall Survival (OS)|Incidence and rate of detection of ONCR-177|Changes in the level of HSV-1 antibodies compared to baseline","Oncorus, Inc.|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","132","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONCR-177-101|KEYNOTE-B73","May 20, 2020","January 2025","July 2028","April 16, 2020",,"May 13, 2021","City of Hope, Duarte, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Ohio State University Wexner Medical Center James Cancer Hospital, Columbus, Ohio, United States|Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas at Austin, Austin, Texas, United States|University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04348916"
89,"NCT02664363","EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma","ExCeL","Terminated","Has Results","Glioblastoma|Gliosarcoma","Biological: EGFRvIII CAR T cells","Maximally Tolerated Dose|Number of Patients Who Experienced a Dose-limiting Toxicity (DLT)","Gary Archer Ph.D.|Duke University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00069444","February 1, 2017","September 25, 2018","September 12, 2019","January 27, 2016","July 24, 2020","July 24, 2020","The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02664363/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02664363"
90,"NCT02977156","Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.","ISI-JX","Active, not recruiting","No Results Available","Metastatic Tumor|Advanced Tumor","Biological: Pexa-Vec|Drug: Ipilimumab","Part A (dose selection part): Dose Limiting Toxicities (DLTs)|Part B (expansion cohort): The 3-month objective response rate (ORR)|3-month objective response rate (ORR)|Best objective response rate|Disease Control Rate|Duration of response|ORR of injected and non injected lesions|Progression Free Survival (PFS)|Time To progression (TTP)|Overall Survival (OS)|Adverse Events reporting","Centre Leon Berard|Transgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET14-035 (ISI-JX)","January 3, 2017","December 2021","March 2022","November 30, 2016",,"November 17, 2021","Institut Bergonie, Bordeaux, France|Centre Léon Bérard, Lyon, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT02977156"
91,"NCT05040217","A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment",,"Recruiting","No Results Available","Alzheimer's Disease","Genetic: AAV2-BDNF Gene Therapy|Biological: AAV2-BDNF Gene Therapy","Safety as assessed by mumber of participants with treatment-related adverse events assessed on MRI scan|Memory change tested on Ray Auditory Verbal Learning Task|Memory change tested on Benson Complex Figure Draw and Memory|Efficacy on PET scan reflected by change in fluorodeoxyglucose (FDG) PET scan|Change in Biomarkers including CSF amyloid, tau and neurofilament|Memory change tested on mini-mental status examination (MMSE)|Memory tested on Alzheimer's Disease Assessment Scale, Cognitive component (ADAS-Cog)","Mark Tuszynski|Case Western Reserve University|Ohio State University|University of California, San Diego","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSD-BDNF1","March 1, 2021","March 1, 2023","March 1, 2025","September 10, 2021",,"September 10, 2021","University of California - San Diego, San Diego, California, United States|Case Western Reserve University, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05040217"
92,"NCT04116710","A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Solid Tumor","Biological: HS-110 (viagenpumatucel-L)|Biological: HS-130","Frequency of TEAEs, SAEs, and DLTs|To determine maximum tolerated dose and optimal immunological dose|Best Overall Response|Overall Survival|Progression-Free Survival|Immunological effect","Heat Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS130-001","October 18, 2019","August 12, 2021","December 2021","October 7, 2019",,"September 24, 2021","Providence Portland Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04116710"
93,"NCT03634332","Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC",,"Unknown status","No Results Available","Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer|Pancreatic Neoplasms","Drug: PEGPH20|Biological: Pembrolizumab","Progression Free Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Overall Response Rate|Disease Control Rate|Duration of Response|Overall Survival","Pancreatic Cancer Research Team|Merck Sharp & Dohme Corp.|Halozyme Therapeutics|University of Washington","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCRT 16-001","May 1, 2019","October 2020","January 2021","August 16, 2018",,"May 7, 2019","Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States|University of Washington--Seattle Cancer Care Alliance, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03634332"
94,"NCT01035645","First Time in Human Study of Intravenous Interleukin-18 Antibody","A18110040","Completed","No Results Available","Inflammatory Bowel Diseases","Drug: GSK1070806","Adverse events, vital signs, cardiac and ECG parameters and clinical laboratory safety assessments.|Plasma concentrations of GSK1070806 and derived pharmacokinetic parameters thereof.|Serum levels of Interleukin-18 (IL-18).|Endpoints of immune function and derived pharmacodynamic parameters thereof.|Serum levels of anti-GSK1070806 binding antibodies.","GlaxoSmithKline","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","110040","January 5, 2010","July 11, 2012","July 11, 2012","December 21, 2009",,"June 12, 2017","GSK Investigational Site, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01035645"
95,"NCT05002517","Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab",,"Active, not recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tociliziumab group|Drug: Methylprednisolone group","Respiratory situation at 24 hours, 3 and 7 days based on the PaO2 / FiO2 ratio that graduates respiratory distress into mild (200-300), moderate (100-200) and severe (<100).|Immune hyperactivation situation: LDH, D-dimer and ferritin value at 24 hours, 3 and 7 days. Each one is a quantitative variable.|Mechanical ventilation: qualitative variable (yes or no)|Combined variable of variables i, iii and in-hospital mortality (this is understood to be: respiratory deterioration or need for mechanical ventilation or in-hospital death)|Number of patients admitted to the ICU|Time to admission to the ICU (from the beginning of the trial and from the beginning of the picture)|Time to the start of mechanical ventilation (from the start of the trial and from the start of the picture)|Time of admission to ICU|Total admission time|In-hospital mortality|Mortality at 30 and 60 days|Respiratory situation at 30 and 60 days according to pulse oximetric O2 saturation, respiratory rate and presence of dyspnea and NYHA grade.|Documented nosocomial infections","Asociacion Instituto Biodonostia","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TOCICOVID","September 3, 2020","July 31, 2021","October 31, 2021","August 12, 2021",,"August 12, 2021","Clinical Research Platform Biodonostia Health Research Institute, San Sebastián, Guipuzcoa, Spain",,"https://ClinicalTrials.gov/show/NCT05002517"
96,"NCT00307125","Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies",,"Completed","Has Results","Kidney Transplant|Kidney Transplant Recipient|Graft Function/Survival|de Novo HLA Antibodies Development","Drug: Rituximab plus immunosuppression|Drug: Placebo plus immunosuppression","During Screening Phase: Incidence of Alloantibody Development|During Screening Phase: Timing of Alloantibody Development|Number of Participants With 50 Percent (%) Decrease in Circulating Anti-Human Leukocyte Antigen (HLA) Antibodies|Number of Deaths 12 Months Post Treatment Initiation|Number of Participants Experiencing Graft Loss 12 Months Post Treatment Initiation|Number of Participants Experiencing Biopsy-proven Post-Transplant Lymphoproliferative Disease (PTLD)|Number of Participants Experiencing Loss of Peritubular Capillary (PTC) C4d Staining on Kidney Biopsy|Number of Participants With Viral Replication of Cytomegalovirus (CMV)|Number of Participants With Evidence of Viral Replication of Epstein-Barr Virus (EBV)|Number of Participants With Viral Replication of Polyomavirus (BKV)","National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation|Cooperative Clinical Trials in Pediatric Transplantation (CCTPT)","All","5 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","757","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT CTOT-02|CCTPT-02","March 2006","December 2012","December 2012","March 27, 2006","March 23, 2015","March 23, 2015","University of Alabama, Pediatric Nephrology, Birmingham, Alabama, United States|University of Alabama, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|University of Illinois, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Legacy Transplant Services, Portland, Oregon, United States|Oregon Health Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Methodist Hospital, Houston, Texas, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00307125"
97,"NCT01514357","Nesiritide in Resistant Hypertension",,"Terminated","Has Results","Hypertension","Drug: Nesiritide (BNP)|Drug: Placebo","Changes in Systolic Blood Pressure (BP)","John C Burnett|National Center for Research Resources (NCRR)|Mayo Clinic","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-001372|UL1RR024150","April 2012","July 2014","July 2014","January 23, 2012","October 20, 2017","March 23, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01514357"
98,"NCT01627002","A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401",,"Terminated","Has Results","Healthy Volunteers","Biological: PA401|Other: Placebo","Treatment Emergent Adverse Events|Immunogenicity|Assessment of the Effect of PA401 on Induced Sputum Total Neutrophils|Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)|Pharmacokinetic Parameters: Time of Occurrence of the Maximum Observed Plasma Concentration (Tmax)|Pharmacokinetic Parameters: Terminal Half-life (t1/2)|Pharmacokinetic Parameters: Area Under the Plasma Concentration-time Curve From Zero to Infinity|Assessment of the Effect of PA401 on Induced Sputum Percentage Neutrophils","ProtAffin Biotechnologie AG","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PA401/01|2012-001189-14","May 2012","April 2013","April 2013","June 25, 2012","September 23, 2013","September 23, 2013","Quintiles, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01627002"
99,"NCT04745559","Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy",,"Recruiting","No Results Available","Diffuse Large-Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|High-grade B-cell Lymphoma (HGBCL)","Biological: Pneumococcal conjugate vaccine (PCV13)|Biological: CD19 targeted CAR T Cell Therapy","Humoral Response Rate -PCV13 vaccine|Increase in PCV13 specific serotype IgG levels|Increase in On-Specific Serotype IgG levels|Response Rate of CD19-targeted CAR T therapy when combined with PCV13 vaccination|Progression Free Survival|Overall Survival","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20571","February 2, 2021","February 2024","February 2025","February 9, 2021",,"July 14, 2021","Moffitt Cancer Center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04745559"
100,"NCT01785043","Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users","LAED001","Completed","No Results Available","DIABETES Mellitus Type 2 Not Well Controlled","Drug: Liraglutide|Drug: Sitagliptin","Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.|The evaluation of other emerging potential cardiovascular risk factors","Anna Cruceta|Fundacion Clinic per a la Recerca Biomédica","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 4","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAED001","March 2013","March 2014","September 2014","February 6, 2013",,"September 15, 2015","Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01785043"
101,"NCT02398656","A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","TEMPO-2","Recruiting","No Results Available","Stroke, Acute","Drug: Tenecteplase|Drug: Antiplatelet treatment","Modified Rankin Scale (mRS)|Major Bleeding","University of Calgary","All","18 Years and older   (Adult, Older Adult)","Phase 3","1274","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Version 3.3 , Mar 24,2017","April 2015","December 2023","December 2023","March 25, 2015",,"November 3, 2020","Calvary Public Hospital Bruce, Canberra, Australian Capital Territory, Australia|John Hunter Hospital, Newcastle, New South Wales, Australia|Gold Coast University Hospital, Gold Coast, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Medical University of Vienna (Coordinating Centre), Vienna, Austria|St. John's of God Hospital Vienna, Vienna, Austria|Hospital de Clínicas de Botucatu, Botucatu, Brazil|Instituto Hospital de Base do Distrito Federal, Brasília, Brazil|Hospital Universitário Maria Aparecida Pedrossian, Campo Grande, Brazil|Hospital Celso Ramos Florianopolos, Celso Ramos, Brazil|Hospital Geral de Fortaleza, Fortaleza, Brazil|Clinica Neurologica e Neurocirurgica de Joinville Ltda, Joinville, Brazil|Porto Alegre Hospital, Porto Alegre, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Brazil|Hospital de Clínicas de Ribeirão Preto, Ribeirão Preto, Brazil|Americas Medical City, Rio De Janeiro, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Hospital São Paulo UNIFESP, São Paulo, Brazil|Irmandade Da Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil|Hospital Estadual Central, Vitória, Brazil|University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Royal Columbian Hospital, New Westminster, B.C., Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western, Toronto, Ontario, Canada|McGill University, Montreal, Quebec, Canada|CHU de Québec-Université Laval, Quebec City, Quebec, Canada|University of Saskatchewan/ Royal University Hospital, Saskatoon, Saskatchewan, Canada|University Central Hospital HUCH, Helsinki, Finland|Beaumont Hospital, Dublin, Leinster, Ireland|Mater Misericordiae University Hospital Dublin, Dublin, Leinster, Ireland|Christchurch Hospital, Christchurch, New Zealand|National Neuroscience Institute Tan Tock Seng Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Complejo Jospitalario Universitario A Coruna, A Coruña, Spain|Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain|Vall d'Hebron Institut de Recerca, Barcelona, Spain|Hospital Universitari Doctor Josep Trueta, Girona, Spain|Clinc University Hospital Valladolid, Valladolid, Spain|Countess of Chester, London, England, United Kingdom|St George's University Hospitals NHS Foundation trust, London, England, United Kingdom|Stoke University of North Midlands, London, England, United Kingdom|University College London Hospital, London, England, United Kingdom|Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Addenbrooke Hospital, Cambridge, United Kingdom|Charring Cross Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02398656"
102,"NCT04146155","Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease",,"Recruiting","No Results Available","Type 2 Diabetes|Peripheral Vascular Disorder Due to Diabetes Mellitus","Drug: Liraglutide+standard-of-care treatment|Other: standard-of-care treatment","Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c","Second Affiliated Hospital, School of Medicine, Zhejiang University","All","40 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","zhengchao","May 1, 2020","December 31, 2021","December 31, 2021","October 31, 2019",,"July 7, 2021","The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04146155"
103,"NCT01469351","Identifying Potential Effects of Liraglutide on Degenerative Changes",,"Completed","No Results Available","Alzheimers Disease","Drug: Liraglutide|Drug: non-active study drug","PIB PET scan|Neuro-psychological tests|FDG PET Scan","University of Aarhus","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011-000794-31","January 2012","April 2013","April 2013","November 10, 2011",,"April 19, 2013","Aarhus University, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT01469351"
104,"NCT03282188","REO13 Melanoma With of Without GM-CSF",,"Withdrawn","No Results Available","Melanoma|Cancer of Skin","Biological: Reolysin|Drug: GM-CSF","Comparison between treatment groups of reovirus tumour infiltration by immunohistochemistry (IHC)|Comparison between treatment groups of reovirus tumour replication, as assessed by qRT-PCR|Comparison between treatment groups of neutralising antibody development development and cell-mediated immune response|Comparison between treatment groups of cell-mediated immune response","University of Leeds|Yorkshire Cancer Research","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MO15/121","October 2017","July 2018","July 2018","September 13, 2017",,"May 4, 2018",,,"https://ClinicalTrials.gov/show/NCT03282188"
105,"NCT02554851","Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.",,"Unknown status","No Results Available","Foot Ulcer, Diabetic|Epidermal Growth Factor","Drug: recombinant human Epidermal Growth Factor (rhEGF)|Other: Placebo","The proportion of participants with 100% healing at the end of follow-up","The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASCLIN002/2015","January 2017","December 2017",,"September 18, 2015",,"June 22, 2016",,,"https://ClinicalTrials.gov/show/NCT02554851"
106,"NCT00879385","KRAS Wild-type Metastatic Colorectal Cancer Trial",,"Completed","No Results Available","Colorectal Cancer","Drug: Dacogen™ (decitabine)|Drug: Vectibix® (panitumumab)","Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.|To examine re-expression or a reduction in promoter methylation in genes involved in tumor suppressor pathways known to be important in colorectal cancer (CRC) or involved in EGFR signaling pathway.|Evaluate overall response (OR = CR +PR) according to RECIST criteria at 2, 4, and 6 cycles. Progression free survival, measured as the first evidence of tumor growth from the start of treatment will also be assessed.|Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.","University of Utah|Amgen|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI31116","December 2009","January 2013","January 2013","April 10, 2009",,"October 31, 2014","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00879385"
107,"NCT02010203","A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT",,"Terminated","Has Results","Bladder Cancer","Biological: HS-410|Biological: Placebo|Biological: BCG","Phase 1: Safety and Tolerability|Phase 2: 1-year Disease-Free Survival|Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months|Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months|Disease-free Survival at 3, 6, 18, and 24 Months|Overall Disease-free Survival|Overall Survival, Expressed as the Number of Participants Alive|Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months|Proportion of Patients Undergoing Cystectomy by 12 and 24 Months|Immunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.|Immunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated|Total PBMC Counts by Flow Cytometry|Tumor Antigen Expression|Tumor Infiltrating Lymphocytes (TILs)|T Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment|Safety of the Combination of the HS-410 and BCG|Safety of the High Dose HS-410 Monotherapy","Heat Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HS410-101","December 2013","December 2017","April 2018","December 12, 2013","February 17, 2020","February 17, 2020","University of California at Los Angeles, Los Angeles, California, United States|Skyline Urology, Sherman Oaks, California, United States|Skyline Urology, Torrance, California, United States|Urology Center of Colorado, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|First Urology, Jeffersonville, Indiana, United States|Horizon Oncology Research, Lafayette, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology of North Texas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Urology of Virginia, Virginia Beach, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02010203/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02010203/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02010203"
108,"NCT02117024","A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer",,"Terminated","Has Results","Non Small Cell Lung Cancer","Drug: Viagenpumatucel-L|Drug: Metronomic Cyclophosphamide|Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)","Overall Survival (OS)|Frequency of Adverse Events: Number of Participants With Treatment-Emergent Adverse Events (TEAE)|Disease Control Rate (DCR)|6-Month Disease Control Rate (6mDCR)|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Survival at 6 Months|Survival at 12 Months|Immune Response","Heat Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS110-201","July 2014","December 2017","April 2018","April 17, 2014","February 5, 2020","February 5, 2020","Highlands Oncology Group, Rogers, Arkansas, United States|University of California San Diego, La Jolla, California, United States|University of California at Los Angeles, Los Angeles, California, United States|University of California Davis, Sacramento, California, United States|Georgia Regents University, Augusta, Georgia, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|SUNY Syracuse, Syracuse, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Providence Portland Medical Center- Providence Lung Cancer Clinic, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Oncology PA Texas Cancer Center, Abilene, Texas, United States|Mary Crowley Cancer Center, Dallas, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States|Aurora Research Institute, Green Bay, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02117024/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02117024"
109,"NCT02107963","A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",,"Completed","No Results Available","Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma","Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide","Feasibility|Determine antitumr effects|Persistence of anti-GD2 CAR T cells and correlate with anti-tumor effects|Evaluate prevalence of GD2 expression|Evaluate effectiveness of AP1903 to mediate clearance of anti-GD2 CAR T cells|Safety","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 35 Years   (Child, Adult)","Phase 1","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140059|14-C-0059","February 28, 2014","August 15, 2016","January 31, 2017","April 9, 2014",,"October 12, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02107963"
110,"NCT02919306","Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults",,"Completed","No Results Available","Human Immunodeficiency Virus","Biological: Ad26.Mos.HIV|Biological: MVA-Mosaic|Drug: Placebo","Number of Participants With Vaccine Related - Grade 3 or Greater Reactogenicity and Adverse Events as a Measure of Safety and Tolerability|Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) less than (<)50 copies per milliliter (copies/ml) at 24 Weeks After Antiretroviral (ARV) Analytical Treatment Interruption (ATI)|Cell-Associated HIV RNA in Total Cluster of Differentiation (CD)4+ Thymus (T) Cells|Cell-Associated HIV RNA in the Memory CD4 Subsets|Cell-Associated Human Immunodeficiency Virus Deoxyribonucleic Acid (HIV DNA) (total, integrated and 2 Long Terminal Repeats [LTR] Circles) in Total CD4+ T Cells|Cell-Associated HIV DNA (Total, Integrated and 2 LTR Circles) in the Memory CD4 Subsets|Quantification of Latent HIV in Total CD4+ T Cells Using a Viral Outgrowth Assay|Quantification of Latent HIV in Memory CD4+ T Cells Using a Viral Outgrowth Assay|Quantification of the Size of the Inducible Viral Reservoir in Total CD4+ T Cells|Quantification of the Size of the Inducible Viral Reservoir in Memory CD4+ T Cells|Single Copy HIV RNA in Samples With HIV RNA <50 copies per milliliter (copies/ml) pre and post Antiretroviral (ARV) Analytical Treatment Interruption (ATI)|Frequency of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)|Magnitude of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)|Breadth of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)|Polyfunctionality of Thymus (T) cell Responses|Number of Binding Antibody to Envelope (Env) Regions|Breadth of antibody neutralization across different HIV-1 strains from different clades will assess immunogenicity as measured in the TZM-bl neutralization assay","Janssen Vaccines & Prevention B.V.","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108161|VAC89220HTX1001","October 2016","September 2018","September 2018","September 29, 2016",,"September 20, 2019","Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02919306"
111,"NCT01087294","Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell","Procedure: Allogeneic stem cell transplant|Biological: Anti-CD19-chimeric-antigen-receptor-transduced T cells|Procedure: Leukapheresis","To assess the safety of allogeneic anti-CD19 CAR|To measure the persistence of anti-CD19-CAR- transduced T cells in the blood of patients after infusion|To determine if administering anti-CD19-CAR-transduced T cells from the original transplant donor can cause regression of B-cell malignancies that are relapsed or persistent after alloHSCT","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","150","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100054|10-C-0054","August 4, 2010","March 1, 2023","March 1, 2024","March 16, 2010",,"November 12, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|National Marrow Donor Program, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01087294"
112,"NCT03103971","huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory B Acute Lymphoblastic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological Study","Incidence of toxicity|Dose-limiting toxicity (DLT) rates|Maximum concentration (Cmax) of autologous human anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014) cells in blood|Time to maximum concentration (Tmax), of huJCAR014 cells in blood|Area under the curve of huJCAR014 cells in blood|Presence of huJCAR014 cells in bone marrow|Complete response (CR) rate|Partial response (PR) rate|Objective response rate (ORR)|Duration of response (DOR)|Progression-free survival (PFS)|Event-free survival (EFS)|Overall survival (OS)","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|Juno Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","78","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9364|NCI-2017-00421|P30CA015704|RG9217000","November 3, 2017","December 31, 2021","December 31, 2022","April 7, 2017",,"September 10, 2021","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03103971"
113,"NCT02858310","E7 TCR T Cells for Human Papillomavirus-Associated Cancers",,"Recruiting","No Results Available","Papillomavirus Infections|Cervical Intraepithelial Neoplasia|Carcinoma In Situ|Vulvar Neoplasms|Vulvar Diseases","Biological: E7 TCR cells|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide","Phase II: Determine safety and effficacy of E7 TCR cells plus aldesleukin|Phase I: Determine a safe dose for E7 TCR cells plus aldesleukin|To assess progression-free survival","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","180","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160154|16-C-0154","January 27, 2017","January 1, 2026","January 1, 2026","August 8, 2016",,"September 27, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02858310"
114,"NCT02439450","A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: Viagenpumatucel-L|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Pemetrexed","Phase 1b: Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.|Phase 2, Arm 5: Objective Response Rate (ORR)|Phase 2, Arm 6: Progression Free Survival (PFS)|Objective Response Rate (ORR)|Overall survival (OS)|Progression-Free survival (PFS)|Duration of response (DOR)|Disease control rate (DCR)|Durable Response Rate (DRR)|Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.","Heat Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","121","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS110-102","April 15, 2015","May 3, 2021","August 2022","May 8, 2015",,"September 28, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego, La Jolla, California, United States|BRRH Lynn Cancer Institute, Boca Raton, Florida, United States|Memorial Cancer Institute, Pembroke Pines, Florida, United States|Horizon Oncology Research, Lafayette, Indiana, United States|Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York Oncology Hematology, Albany, New York, United States|Winthrop Hospital, Mineola, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02439450"
115,"NCT03083743","A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection",,"Unknown status","No Results Available","Non-small-cell Lung Cancer (NSCLC) Stage IV","Biological: Recombinant human Apo-2 ligand for Injection|Biological: Placebo","Overall Survival（OS）|Progression - free survival（PFS）|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Quality of Life (QoL)","Shanghai Gebaide Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","417","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016L04304","October 2016","October 2017","June 2018","March 20, 2017",,"March 20, 2017","Cancer Hospital，Chinese Academy of Medical Sciences, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03083743"
116,"NCT00102245","Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes",,"Terminated","No Results Available","Hemoglobinopathies|Hemolysis|Iron Deficiency and Overload|Anemias",,,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","1 Year and older   (Child, Adult, Older Adult)",,"334","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","050085|05-DK-0085","January 18, 2005",,"August 4, 2017","January 26, 2005",,"February 14, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00102245"
117,"NCT03983460","Dupilumab Impact on Skin Resident Memory T Cells","DupiTrem","Recruiting","No Results Available","Atopic Dermatitis","Drug: Dupilumab|Drug: Optimized TCS treatment|Procedure: Biopsies|Procedure: Skin prick-test|Procedure: Blood sample collection","To assess the change of the number (per biopsy or per mL of blood) and/or frequency (among live hematopoietic cells CD45+) of immune cells that are present in the skin and the blood of AD patients after Dupilumab or TCS treatment.|To investigate correlations between each immunological parameter and each clinical score as a continuous quantitative variable, as well as each immunological parameter and quality of life index as a continuous quantitative variable.|To investigate correlations between each immunological parameter and change in clinical score as a qualitative variable with 2 modalities as well as each immunological parameter and quality of life index, as a qualitative variable with 2 modalities.|To investigate correlations between each immunological parameter and the development of new AD lesions in the 3 following months, as well as each immunological parameter and the interval of time between the end of treatment and AD relapse.","Association pour la Recherche Clinique et Immunologique","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","18082A0002","March 9, 2020","June 2021","September 2021","June 12, 2019",,"March 24, 2020","Service d'Allergologie et Immunologie Clinique - Hôpital Lyon Sud, Pierre-Bénite, France",,"https://ClinicalTrials.gov/show/NCT03983460"
118,"NCT03994172","Novel Combination Therapy for Osteoporosis in Men","Osteo-Men","Recruiting","No Results Available","Male Osteoporosis","Drug: Teriparatide or human parathyroid hormone (PTH) 1-34|Drug: Cinacalcet|Drug: placebo tablet|Dietary Supplement: Calcium citrate tablet|Dietary Supplement: Vitamin D3","Effects of treatment with TPTD+cinacalcet compared to TPTD+PBO on lumbar spine BMD in men with low bone mass|Effects of treatment with TPTD+cinacalcet compared to TPTD+PBO on serum P1NP in men with low bone mass|Effects of treatment with TPTD+cinacalcet compared to TPTD+PBO on femoral neck BMD in men with low bone mass","VA Office of Research and Development|University of California, San Francisco","Male","60 Years to 85 Years   (Adult, Older Adult)","Phase 4","48","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ENDB-012-17F|1 IO1 CX001514-01A2","July 1, 2019","June 30, 2023","June 30, 2024","June 21, 2019",,"December 22, 2020","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03994172"
119,"NCT02315703","Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention",,"Active, not recruiting","Has Results","Healthy","Biological: Ad26.Mos.HIV|Biological: MVA-Mosaic|Biological: gp140 DP Low-dose|Biological: gp140 DP High-dose|Drug: Placebo","Percentage of Participants With Solicited Local Adverse Events (AEs) Post Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) Post Vaccination|Percentage of Participants With Unsolicited Adverse Events Post Vaccination|Number of Participants With Serious Adverse Events (SAEs) Post Vaccination|Percentage of Responders for Envelop (Env) Clade A, B and C-specific Binding Antibody Titers at Week 28|Percentage of Responders for Clade C (C97ZA.012) Env Enzyme-linked Immunosorbent Assay (ELISA) Immunoglobulin G1 (IgG1), IgG2, IgG3 and IgG4 Gylcoprotein (gp) 140 Binding Antibody|Percentage of Responders for Env ELISA Including Consensus C and Mos1 Antigens|Percentage of Responders for Env Antibody-dependent Cellular Phagocytosis (ADCP) gp Antibody|Percentage of Responders for Human Immunodeficiency Virus Neutralizing Antibody (HIV nAb)|Percentage of Responders for Binding Antibody Multiplex Assay (BAMA) IgG1-IgG4 and IgA and IgG-t Breadth Antibody|Percentage of Responders With Interferon-gamma (IFN-gamma) T Cell Responses Enzyme-linked Immunospot Assay (ELISpot)","Janssen Vaccines & Prevention B.V.|National Institute of Allergy and Infectious Diseases (NIAID)|US Military HIV Research Program|Beth Israel Deaconess Medical Center|International AIDS Vaccine Initiative","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","393","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CR106152|HIV-V-A004|IPCAVD009","December 2014","August 2017","July 2022","December 12, 2014","November 4, 2020","November 24, 2021","Aurora, Colorado, United States|Miami, Florida, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Austin, Texas, United States|Kigali, Rwanda|Cape Town, South Africa|Durban, South Africa|Johannesburg, South Africa|Bangkok, Thailand|Entebbe, Uganda|Kampala, Uganda","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02315703/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02315703/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02315703"
120,"NCT03695939","Evaluation of Safety, Tolerability and Efficacy of Xeno-Skin® for Temporary Closure of Severe Burn Wounds",,"Recruiting","No Results Available","Deep Full-thickness Burn Injury (Disorder)","Biological: Xeno-Skin™|Biological: Human Cadaver Allograft","Temporary Wound Closure|Long-term Safety and Tolerability|Definitive Wound Closure|Improved Wound Healing","XenoTherapeutics, Inc.|Massachusetts General Hospital|Joseph M. Still Research Foundation, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P001839","March 15, 2019","March 31, 2022","July 31, 2022","October 4, 2018",,"October 21, 2021","JMS Burn Center at Doctors Hospital, Augusta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03695939"
121,"NCT03844061","Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis",,"Recruiting","No Results Available","Systemic Sclerosis","Drug: Belimumab|Drug: Rituximab|Other: Placebo Subcutaneous Injection|Other: Placebo Infusion|Drug: MMF","Primary Efficacy Outcome: Change in the ACR CRISS at 12 months|Primary Safety Outcome: The proportion of participants who experience at least one Grade 3 or higher adverse event at or before 12 months|Proportion of patients who experience at least one grade 2 or higher adverse event|Number Infectious Adverse Events Across all Participants|Number Adverse Infusion Reactions Across all Participants|Number Injection Site Reactions Across all Participants|Number Adverse Events Across all Participants|Change in the CRISS at 6 months|Change in the MRSS at 6 and 12 months|Change in FVC and DLCO|Forced Vital Capacity (FVC)|Changes in the Short Form-36 (SF-36) Health Survey|Change in the scleroderma health assessment questionnaire-disability index (sHAQ-DI)|Change in PROMIS-29|Change in gastrointestinal tract (GIT) in scleroderma score|Change in Scleroderma Skin Patient Reported Outcome (SSPRO)|Change in Disease Activity Score 28 (DAS-28)|Change in joint count|Change in Clinical Disease Activity Index (CDAI): Measures joint tenderness and swelling|Change in Global Combined Response Index","Hospital for Special Surgery, New York|GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2018-2011","July 29, 2019","February 28, 2022","February 28, 2022","February 18, 2019",,"October 5, 2021","Hospital for Special Surgery, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03844061/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03844061/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03844061"
122,"NCT02134262","Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",,"Unknown status","No Results Available","Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Drug: Cyclophosphamide or Bendamustine|Genetic: Dose Level -1|Genetic: Dose Level 1|Genetic: Dose Level 2|Genetic: Dose Level 3","Toxicity Profile|Quality test of CD19-CAR-T|Tumor shrinkage effect|Lymphocyte subset analysis of CD19-CAR-T|Human anti-mouse antibody (HAMA) test","Jichi Medical University|Takara Bio Inc.","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JMU-CD19CAR","May 2014","March 2017","March 2017","May 9, 2014",,"November 6, 2014","Jichi Medical University, Shimotsuke, Tochigi, Japan",,"https://ClinicalTrials.gov/show/NCT02134262"
123,"NCT03155191","Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","TBI-1501","Recruiting","No Results Available","Lymphoblastic Leukemia, Acute Adult","Biological: TBI-1501","Phase-I portion: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Phase-II portion: Anti-tumor effect (CR+CRi rate)","Takara Bio Inc.|Otsuka Pharmaceutical Co., Ltd.","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1501-01","June 1, 2017","March 31, 2035","March 31, 2035","May 16, 2017",,"December 28, 2020","University Of Fukui Hospital, Yoshida, Fukui, Japan|Kyushu University Hospital, Higashi-ku, Fukuoka, Japan|Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Mie University Hospital, Tsu-shi, Mie, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Jichi Medical University hospital, Shimotsuke-shi, Tochigi, Japan|Cancer Institute Hospital Of JFCR, Kōto, Tokyo, Japan|The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan|Akita University Hospital, Akita, Japan|Okayama University Hospital, Okayama, Japan",,"https://ClinicalTrials.gov/show/NCT03155191"
124,"NCT04066881","A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","PrEPVacc","Not yet recruiting","No Results Available","HIV Infections","Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Drug: Control PrEP:TDF/FTC once daily (weeks 0-26)|Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26)","Incident HIV infection|A clinical decision to discontinue the vaccine regimen for an adverse event that is considered related to product|A clinical decision to discontinue PrEP regimen for an adverse event that is considered related to product|Grade 3 and worse solicited clinical and laboratory adverse events|Discontinuation or interruption of vaccine regimen|Discontinuation or interruption of PrEP|Serious adverse events|Other clinical and laboratory adverse events|Binding antibodies|Resistance mutations to tenofovir and emtricitabine|Number of PrEP pills missed|Tenofovir level in urine|Tenofovir level in red blood cells|Number of PrEP Pills dispensed","MRC/UVRI and LSHTM Uganda Research Unit|Imperial College London|University College, London|International AIDS Vaccine Initiative|EuroVacc Foundation|Medical Research Council, South Africa|National Institute for Medical Research, Tanzania|Muhimbili University of Health and Allied Sciences|Instituto Nacional de Saúde, Mozambique|Ludwig-Maximilians - University of Munich|King's College London|Centre Hospitalier Universitaire Vaudois|Karolinska Institutet|CONRAD|Gilead Sciences","All","18 Years to 40 Years   (Adult)","Phase 2","1668","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PV1","January 2020","March 2023","March 2023","August 26, 2019",,"August 26, 2019","MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda",,"https://ClinicalTrials.gov/show/NCT04066881"
125,"NCT05052957","hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","hSTAR GBM","Not yet recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma Multiforme, Adult|Supratentorial Glioblastoma|Supratentorial Gliosarcoma","Biological: P140K-MGMT|Drug: O6-benzylguanine|Radiation: Photon Based Radiotherapy|Drug: temozolomide|Drug: Filgrastim|Drug: carmustine","Percent of participants able to complete treatment|Incidence of adverse events|Overall Survival|Myelosuppression|Detection of P140K transduced BG and TMZ resistant cells|Enrichment of P140K-MGMT|Tumor Response using imaging|PFS using imaging","Andrew Sloan, MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE5320|1U01CA236215-01","October 15, 2021","June 1, 2023","December 1, 2023","September 22, 2021",,"October 7, 2021","NIH-Clinical Center, Bethesda, Maryland, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05052957"
126,"NCT04558736","Haploidentical HCT for Severe Aplastic Anemia",,"Recruiting","No Results Available","Aplastic Anemia|Bone Marrow Failure Syndrome","Drug: Anti-Thymocyte Globulin (Rabbit)|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Drug: G-CSF|Radiation: Total Lymphoid Irradiation (TLI)|Device: CliniMACS|Biological: HPC, A Infusion|Biological: CD45RA-depleted DLI","Engraftment|Overall and event free survival|Graft vs host disease|Graft rejection|Viral reactivation|Immune reconstitution","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAPSAA","January 21, 2021","July 1, 2025","July 1, 2026","September 22, 2020",,"September 1, 2021","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04558736"
127,"NCT03849651","TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)|NK-Cell Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma (NHL)|Juvenile Myelomonocytic Leukemia (JMML)|Chronic Myeloid Leukemia (CML)","Drug: Cyclophosphamide|Biological: Fludarabine|Drug: Thiotepa|Drug: Melphalan|Biological: G-csf|Drug: Mesna|Device: CliniMACS|Biological: ATG (rabbit)|Drug: Blinatumomab|Biological: TCRα/β+|Biological: CD19+|Biological: CD45RA-depleted DLI","Maximum effective dose for prophylactic CD45RA-depleted DLI|One-year Event Free Survival (EFS) after completion of the protocol|The number of patients experiencing Blinatumomab permanent discontinuation due to toxicity|The estimate of cumulative incidence of relapse|The cumulative incidence of acute and chronic Graft-Versus-Host Disease (GVHD)|The cumulative incidence of transplant related mortality","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","140","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAP2HCT","January 31, 2019","July 1, 2024","July 1, 2025","February 21, 2019",,"October 12, 2021","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03849651"
128,"NCT02942277","Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali",,"Completed","No Results Available","Malaria","Biological: Pfs25M-EPA|Biological: Pfs230D1M-EPA|Other: AS01|Biological: Engerix-B|Biological: Menactra|Other: Normal Saline|Drug: Coartem","Incidence of local and systemic adverse events (AEs) and serious adverse events (SAEs) in Malian adults. (All arms)|Measurement of Anti-Pfs25 and Pfs230 IgG levels","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 52 Years   (Adult)","Phase 1","591","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","999917006|17-I-N006","October 21, 2016","July 15, 2020","July 15, 2020","October 24, 2016",,"August 4, 2020","Bancoumana Malaria Vaccine Center, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT02942277"
129,"NCT03081455","Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes",,"Completed","No Results Available","Hereditary Cancer","Diagnostic Test: Diagnostic Test","The percentage of previously untested patients meeting guidelines who are offered genetic testing on site.|The number of previously untested patients meeting guidelines who agree to undergo genetic testing without a pre-test referral to a genetic counselor.","Myriad Genetic Laboratories, Inc.|Myriad Genetics, Inc.","Female","18 Years and older   (Adult, Older Adult)",,"145","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PC-005","February 13, 2017","July 7, 2017","August 4, 2017","March 16, 2017",,"August 8, 2017","Westwood Women's Health, Waterbury, Connecticut, United States|Associates for Women's Medicine, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT03081455"
130,"NCT00914628","Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia","TK008","Terminated","Has Results","Acute Leukemia (Category)","Genetic: HSV-Tk|Other: T-cell depleted or T-cell replete strategies","Disease-free Survival (DFS)|Overall Survival (OS)|Immune Reconstitution (IR)|Engraftment Rate|Cumulative Incidence of Grade 2, 3, or 4 Acute GvHD (aGvHD)|Cumulative Incidence of Chronic GvHD (cGvHD)|Duration of GvHD Episodes|Cumulative Incidence of Relapse (CIR)|Incidence and Duration of Infectious Episodes and Infectious Disease Mortality|Evaluate the Acute and Long-term Toxicity Related to the HSV-Tk Infusions|Quality of Life (QoL) and Medical Care Utilization (MCU) in Both Arms|Non-relapse Mortality (NRM)","AGC Biologics S.p.A.","All","18 Years and older   (Adult, Older Adult)","Phase 3","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TK008|2009-012973-37","April 12, 2010","November 30, 2019","November 30, 2019","June 5, 2009","June 22, 2021","June 22, 2021","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Washington University Medical School, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Universitair Ziekenhuis, Gent, Belgium|University Hospitals Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman, Liège, Belgium|Hôpital Jean Minjoz, Besançon, France|Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Institut Paoli-Calmettes, Marseille, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Hôpital l'Archet, Nice, France|Hôpital Saint-Antoine, Paris, France|IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Toulouse, France|Charitè; Campus Benjamin Franklin, Berlin, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|University of Leipzig, Leipzig, Germany|Universitat Tubingen, Tubingen, Germany|Medizinische Klinik und Poliklinik, Ulm, Germany|George Papanicolaou Hospital, Thessaloniki, Greece|Chaim Sheba Medical Center, Tel Hashomer, Israel|Azienda Sanitaria Ospedaliera S.Croce e Carle, Cuneo, CN, Italy|Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele, Catania, CT, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, FI, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello, Palermo, PA, Italy|Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, TO, Italy|Ospedale Santa Maria della Misericordia, Udine, UD, Italy|Policlinico G. B. Rossi, Azienda ospedaliera universitaria integrata di Verona, Verona, VR, Italy|Ospedale San Raffaele, Milan, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy|Santaros Klinikos, Vilnius, Lithuania|Centro Hospitalar Lisboa Norte, E.P.E., Lisboa, Portugal|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Spain|Hospital de Navarra, Pamplona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT00914628/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00914628"
